[User]
<|image|>Parse the figure content behind with markdown code: <md> | Task performed | <COLSPAN=2> < 5 years (N = 296) | <COLSPAN=2> ≥ 5 years (N = 373) | <COLSPAN=2> All patients (N = 669) |
 |  | n (%) | 95% CI | n (%) | 95% CI | n (%) | 95% CI |
 | --- | --- | --- | --- | --- | --- | --- |
 | Weight measured | 192 (64.9) | 55.9–73.8 | 151 (40.5) | 30.9–50.1 | 343 (51.3) | 43.2–59.4 |
 | First dose given at the facility | 40 (13.5) | 7.4–19.7 | 58 (15.6) | 8.4–22.7 | 98 (14.7) | 8.5–20.8 |
 | Swallowing of first dose observed | 34 (11.5) | 5.3–17.6 | 56 (15.0) | 7.8–22.2 | 90(13.5) | 7.3–19.7 |
 | Dosage explained | 284 (96.0) | 93.3–98.6 | 363 (97.3) | 95.1–99.5 | 647 (96.7) | 94.7–98.7

[Assistant]
|
 | Advice provided to complete all doses | 185 (62.5) | 55.1–69.9 | 262 (70.2) | 64.1–76.4 | 447 (66.8) | 61.3–72.3 |
 | Advice provided to take drug after a meal | 132 (44.6) | 37.1–52.1 | 182 (48.8) | 42.7–54.9 | 314 (46.9) | 41.3–52.6 |
 | Advice provided what to do if vomiting | 24 (8.1) | 2.9–13.3 | 20 (5.4) | 2.1–8.6 | 44 (6.6) | 3.1–10.1 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Variable * | ISA | FSA | Difference | 95% CI | p Value |
 | --- | --- | --- | --- | --- | --- |
 | M-L sway (EO) (cm) | 1.2 ± 0.6 | 3.7 ± 1.2 | 2.5 | 2.2 to 2.8 | <0.001 |
 | M-L sway (EC) (cm) | 1.4 ± 0.8 | 4.6 ± 1.5 | 3.2 | 2.8 to 3.6 | <0.001 |

[Assistant]
| M-L sway (FEO) (cm) | 2.7 ± 1.0 | 7.0 ± 4.2 | 4.3 | 3.3 to 5.2 | <0.001 |
 | M-L sway (FEC) (cm) | 4.9 ± 1.7 | 11.5 ± 6.2 | 6.6 | 5.3 to 7.9 | <0.001 |
 | Four Square (sec) | 8.6 ± 2.2 | 9.0 ± 2.5 | 0.4 | 0.0 to 0.8 | 0.036 |
 | TUG (sec) | 6.8 ± 1.6 | 7.9 ± 2.2 | 1.1 | 0.7 to 1.4 | <0.001 |
 | Ankle Strength (kg) | 10.6 ± 4.3 | 10.7 ± 3.4 | −0.1 | −0.9 to 0.6 | 0.748 |
 | Knee Strength (kg) | 19.5 ± 6.9 | 19.4 ± 6.9 | −0.1 | −0.9 to 0.7 | 0.818 |
 | Caloric Expenditure (Cal/Day) | 4,337 ± 287 | 3,428 ± 278 | −909 | −348 to −1,471 | 0.002 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> |  |  | <COLSPAN=2> DM HLOD | <COLSPAN=2> RM HLOD |
 | --- | --- | --- | --- | --- | --- |
 | CHR | Family | SNP-GWS | SNP-GWS + STRs | STR-GWS | STR-GWS + STRs |
 | 2 | 3395 | 1.73 | 1.92 | NL | NL |
 | 4 | 2191 | 1.8 | 1.8 | 1.74 | 1.75 |
 | 11 | 153 | 2.2 | 2.2 | 1.78

[Assistant]
| 1.98 |
 | 14 | 153 | 2.2 | 2.2 | NL | NL | </md>


[User] <|image|>Transcribe the image into Markdown format.

[Assistant]
<md> | Parameter | Value |
 | --- | --- |
 | No of IP-WSN Node (N) | 25∼120 |
 | Network Area (A) | 120 × 120 M |
 | Node density (ρ) | 0.00173∼0.00833 |
 | Initial Energy | 2 J |
 | Transmit/Receive electronics (LE) | 50 nJ bit−1 m2 |
 | Transmission Power | 5.85 × 10−5 W |
 | Number of SMAG | 1–10 |
 | Transmission range (r) | 25 m |
 | Packet size | 2 KB | </md>


[User] <|image|>Convert the picture into Markdown format.

[Assistant]
<md> | Mal3 (nM) | Growth (mean±s.e.m. (n), nm s−1) | Shrinkage (mean±s.e.m. (n), nm s−1) | Catastrophe (frequency±CL (n), min−1) | Rescue (frequency±CL (n), min−1) |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Plus end |
 | 0 | 7.44±0.44 (148) | 227.6±14.0 (136) | 0.43±0.36/0.51 (137) | 0.29±0.06/0.85 (3) |
 | 1 | 7.25±0.27 (138) | 240.4±14.3 (126)* | 0.49±0.41/0.58 (129) | 0.00±0.00/3.69 (0) |
 | 10 | 6.03±0.29 (88) | 316.0±26.4 (84) | 0.48±0.38/0.59 (85) | 0.22±0.01/1.22 (1) |
 | 50 | 7.20±0.53 (97) | 213.2±17.5 (88) | 0.48±0.38/0.59 (82) | 0.88±0.32/1.92 (6) |
 | 100 | 9.12±0.38 (116)* | 107.6±7.5 (108)* | 0.56±0.46/0.68 (107) | 4.33±3.44/5.37 (82)† |
 |  |  |  |  |  |
 | <COLSPAN=5> Minus end |
 | 0 | 2.90±0.27 (71) | 109.3±8.3 (59) | 0.18±0.14/0.23 (57) | 2.26±1.68/2.98 (50) |
 | 1 | 3.17±0.33 (63) | 113.4±9.1 (53) | 0.22±0.17/0.29 (53) | 2.75±1.63/4.34 (18) |
 | 10 | 2.10±0.59 (17) | 115.4±24.3 (14) | 0.15±0.08/0.26 (14) | 3.84±1.24/8.95 (5) |
 | 50 | 2.94±0.78 (39) | 66.2±10.3 (58)* | 0.24±0.17/0.34 (33) | 0.59±0.40/0.84 (30) |
 | 100 | 1.53±0.25 (14) | 60.6±9.5 (5) | 0.03±0.01/0.06 (5) | 5.52±1.79/12.89 (5) | </md>


[User] <|image|>Interpret the table as Markdown format.

[Assistant]
<md> | Replication level | Testing validity | Scope of generality |
 | --- | --- | --- |
 | Exact (close) replication | Excellent | Narrowly defined biological phenomenon limited to a population, strain, or locality |
 | Partial replication | Good | Fairly narrowly defined biological phenomenon mostly limited to a population, strain, or locality |
 | Conceptual replication | Poor | Species- or system-specific phenomenon, broadly defined |
 | Quasi-replication (partial) | Poor | Narrowly defined biological phenomenon across species or system |
 | Quasi-replication (conceptual) | Poor | Broadly defined biological phenomenon across species or systems | </md>


[User] <|image|>Translate the figure into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Variable | <ROWSPAN=2> AAS users | <COLSPAN=3> Non-user |
 | With intentions to use | With undetermined intentions | With no intentions to use |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> Having an optimally muscular body can only be achieved by using AAS |
 | True | 70.5 % | 67 % | 34 % | 19 % |
 | False | 25 % | 24 % | 36 % | 51 % |
 | I don’t know | 4.5 % | 9 % | 30 % | 30 % |
 | <COLSPAN=5> Do you personally know an AAS user? |
 | Yes | 99.78 % | 90.5 % | 80 % | 64.3 % |
 | <COLSPAN=5> Is AAS harmful? |
 | Yes, very harmful | 6.8 % | 9.5 % | 20 % | 50 % |
 | Not very harmful | 29.5 % | 42.9 % | 33.3 % | 14.3 % |
 | No, not if it was used correctly | 56.8 % | 42.9 % | 24.4 % | 19 % |
 | I don’t know | 6.8 % | 4.8 % | 22.2 % | 16.7 % |
 | <COLSPAN=5> Use many (>3) supplements and aids to achieve his goals in the gym (other than AAS) |
 | Does | 80 % | 28.6 % | 24.4 % | 10.7 % | </md>


[User] <|image|>Convert the image to Markdown syntax.

[Assistant]
<md> | Entry | Substrate | Reaction time (h) | Conversion (%) | ee of (R)-1 (%) |
 | --- | --- | --- | --- | --- |
 | 1 | rac-1a | 2 | 95.2 | >99 |
 | 2 | rac-1b | 2 | 92.7 | >99 |
 | 3 | rac-1c | 2 | 95.8 | >99 |
 | 4 | rac-1d | 4 | 95.9 | >99 |
 | 5 | rac-1e | 2 | 98.5 | >99 |
 | 6 | rac-1f | 2 | 98.2 | >99 |
 | 7 | rac-1g | 2 | 97.4 | >99 |
 | 8 | rac-1h | 2 | 97.7 | >99 |
 | 9 | rac-1i | 2 | 96.6 | >99 |
 | 10 | rac-1j | 2 | 97.1 | >99 |
 | 11 | rac-1k | 2 | 97.4 | >99 |
 | 12 | rac-1l | 2 | 96.9 | >99 |
 | 13 | rac-1m | 2 | 97.7 | >99 |
 | 14 | rac-1n | 6 | 37.4 | 91.5 |
 | 15 | rac-1o | 6 | 33.9 | 73.6 |
 | 16 | rac-1p | 6 | 76.9 | >99 |
 | 17 | rac-1q | 6 | 40.5 | >99 |
 | 18 | rac-1r | 6 | 90.7 | 85.8 |
 | 19 | rac-1s | 6 | 82.4 | 78.6 | </md>


[User] <|image|>Transcribe the diagram into Markdown format.

[Assistant]
<md> | Subgroup | <COLSPAN=6> Domain (Mean ± SD) |
 |  | Scope and purpose (%) | Stakeholder involvement (%) | Rigor of development (%) | Clarity of presentation (%) | Applicability (%) | Editorial independence % |
 | --- | --- | --- | --- | --- | --- | --- |
 | Evidence-based guideline | 89.93 ± 7.38 | 65.63 ± 18.78 | 73.57 ± 8.74 | 90.97 ± 3.67 | 49.22 ± 11.95 | 43.75 ± 37.65 |
 | Non Evidence-based guideline | 55.10 ± 24.51* | 27.54 ± 17.71* | 25.87 ± 6.83* | 78.24 ± 6.25* | 29.69 ± 7.02* | 10.41 ± 16.17 | </md>


[User] <|image|>Convert the image into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> AID | <ROWSPAN=2> Target | <COLSPAN=6> Number of compounds |
 | Tested | Active | Inactive | Inconclusive | Unspecified | Non-inactive |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=8> PMID 17346963 |
 | 295044 | RDH9 (GI 74752227)a | 3 | 1 | 0 | 0 | 2 | 3 |
 | <COLSPAN=8> PMID 18707087 |
 | 365154 | Rhodopsin (GI 129204) | 2 | 1 | 0 | 0 | 1 | 2 |
 | 365155 | Rhodopsin (GI 129204) | 2 | 1 | 0 | 0 | 1 | 2 |
 | 365156 | Rhodopsin (GI 129204) | 6 | 6 | 0 | 0 | 0 | 6 |
 | <COLSPAN=8> PMID 21309593 |
 | 591677 | Rhodopsin (GI 129204) | 14 | 0 | 0 | 8 | 6 | 14 |
 | <COLSPAN=8> PMID 21591606 |
 | 606062 | RBP4 (GI 62298174)b | 8 | 8 | 0 | 0 | 0 | 8 |
 | 606063 | RBP4 (GI 62298174) | 21 | 0 | 21 | 0 | 0 | 0 |
 | 606064 | RBP4 (GI 62298174) | 47 | 46 | 0 | 0 | 1 | 47 |
 | 606065 | RBP4 (GI 62298174) | 1 | 0 | 0 | 0 | 1 | 1 |
 | 606066 | RBP4 (GI 62298174) | 7 | 7 | 0 | 0 | 0 | 7 |
 | 606161 | RBP4 (GI 62298174) | 7 | 7 | 0 | 0 | 0 | 7 |
 | 606162 | RBP4 (GI 62298174) | 2 | 1 | 1 | 0 | 0 | 1 |
 | 606163 | RBP4 (GI 62298174) | 7 | 6 | 1 | 0 | 0 | 6 | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Parameter | Group | 6 weeks | 12 weeks | 26 weeks |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=3> New bone | Allograft | 2.6 ± 0.9 | 2.0 ± 0.8 | 1.8 ± 1.0 |
 | PEEK Optima HA | 2.0 ± 0.8 | 2.8 ± 0.5 | 3.0 ± 0.0 |
 | PEEK Optima Natural | 1.0 ± 0.0 | 3.0 ± 0.0 | 3.0 ± 0.0 |
 | <ROWSPAN=3> Quality | Allograft | 1.2 ± 1.3 | 0.5 ± 0.6 | 0.8 ± 1.5 |
 | PEEK Optima HA | 1.0 ± 1.4 | 1.5 ± 1.3 | 1.8 ± 1.0 |
 | PEEK Optima Natural | 0.0 ± 0.0

[Assistant]
| 0.8 ± 1.0 | 1.8 ± 1.5 |
 | <ROWSPAN=3> Contact | Allograft | 1.8 ± 1.3 | 1.3 ± 1.5 | 2.0 ± 1.2 |
 | PEEK Optima HA | 0.5 ± 0.6 | 1.5 ± 1.0 | 1.3 ± 0.5 |
 | PEEK Optima Natural | 0.0 ± 0.0 | 0.5 ± 0.6 | 1.0 ± 1.4 | </md>


[User]
<|image|>Continue parse the photo with markdown style: <md> | Variable | ISOS | RSQ | PANSS-G | PANSS-N | PANSS-P |
 | --- | --- | --- | --- | --- | --- |
 | Annual cost |  |

[Assistant]
|  |  |  |
 | Pearson correlation | −0.079 | −0.018 | 0.452 | 0.203 | 0.333 |
 | P-value | 0.580 | 0.897 | 0.001 | 0.150 | 0.016 | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | Variables |  | <COLSPAN=2> Prevalence |  |  |  |
 |  |  | % | (95%CI) | n | OR (95%CI) | ORaj (95%CI) |
 | --- | --- | --- | --- | --- | --- | --- |
 | Sex | male | 73.4 | (69.8–77.0) | 572 | 1.06 (0.83–1.36) |  |
 |  | female | 72.2 | (68.9–75.5) | 720 | 1 |  |
 | Birthplace | Catalonia | 65.5 | (62.4–68.6) | 890 | 1 | 1 |
 |  | Other place | 89.7 | (86.6–92.8) | 378 | 4.57 (3.15–6.66)1 | 1.75 (1.11–2.76)2 |
 | Habitat | urban |

[Assistant]
71.9 | (69.2–74.6) | 1070 | 1 |  |
 |  | rural | 77.0 | (71.0–83.0) | 222 | 1.31 (0.93–1.84) |  |
 | Social class | I-III | 66.7 | (62.5–70.9) | 492 | 1 | 1 |
 |  | IV-V | 77.5 | (74.2–80.8) | 618 | 1.72 (1.31–2.27)1 | 1.14 (1.05–1.25)3 | </md>


[User]
<|image|>Parse the illustration content behind with markdown code: <md> | Variable | 0 pack years (n = 61 | 1 to 15 pack years (n = 37) | 16 to 30 pack years (n = 17) | > 30 pack years (n = 14) | P (trend)a |
 | --- | --- | --- | --- | --- | --- |
 | PC3 | -0.10 (1.80) |

[Assistant] 0.38 (1.17) | 0.79 (1.21) | 1.86 (2.51) | < 0.0005 | </md>


[User]
<|image|>Parse the following content of the table in markdown code: <md> | Foods and Fluids | Consumption Level |
 | --- | --- |
 | Meats and sweet desserts—1 to 2 days a week | Low |
 | Yogurt, low-fat cheese, poultry, and eggs—5 to 7 days a week | Moderate |
 | Fish and seafood—5 to 7 days a week | Moderate |
 | Nuts and seeds—every day | Moderate |
 | Fruits, vegetables, whole grains, and legumes—every day | High

[Assistant]
|
 | Olives and olive oil—every day | High |
 | Herbs, spices, and garlic | High |
 | Wine—2 servings/day (M) or 1 per day (F) | Moderate |
 | Water | High | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> | Time | WBC (×103/uL) | Hemoglobin (×103/uL) | Platelet count (×103/uL) | Haptoglobin (mg/dL) | LDH (u/L) | Reticulocyte count | T. Bilirubin (mg/dL) | Creatinine (mg/dL) | BUN (mg/dL) | INR | PTT | Fibrinogen |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Initial presentation at another hospital | 11 | 11.1 | 30 | <3.0 | 2391 | 3.70 % | 2.2 | 2.49 | 73 | 1.20 | 26.0 | 577 |
 | H0, ICU admission at our center | 7.6 | 6.4 | 57 | NA | 4576 | 6.20 % | 1 | 6.8 | 112 | 1.43 | 35.8 | 412 |
 | H1, 1 day after receiving plasmapheresis | 7.4 | 7.9 | 62 | NA | 992 | NA | 1 | 5.79 | 104 | 1.36 | 30.9 | NA |
 | H2, 2 days after receiving plasmapheresis | 14.9 | 8.2 | 58 | NA | 1639 | 4.90 % | 1.5 | 6.22 | 122 | NA | NA | NA |
 | H3, day stopped plasmapheresis | 16.8 | 8.9 | 33 | NA | 2489 | 4.10 % | 2.1 | 4.78 | 117 | 1.40 | 38.8 | 148 | </md>


[User] <|image|>Convert the photo into Markdown language.

[Assistant]
<md> | Study | Year | HPV type | Mode of Detection | Tumor Type |
 | --- | --- | --- | --- | --- |
 | Fischer et al [60] | 2005 | Different HPV types | Applied broad-spectrum PCR | Benign lesions |
 | Castro et al [59] | 2006 | 6/11 | Review | Squamous cell papilloma |
 | Martins et al [56] | 2008 | 6 | HPV typing (PCR), light microscopy and electron microscopy | Laryngeal papillomatosis |
 | Förster et al [57] | 2008 | 6/11 | PCR | Juvenile laryngeal papillomatosis |
 | DeVoti et al [58] | 2008 | 6/11 | PCR, micro array | Respiratory papillomas (RP) |
 | Kovalenko et al[55] | 2009 | 6/11 | IHC | Respiratory papillomatosis | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | <COLSPAN=4> Never-Smokers | <COLSPAN=4> Ever-Smokers | <COLSPAN=4> Smoking History Unknown |
 | Grade | EGFR Mutation Negative | EGFR Mutation Positive | p Value | Grade | EGFR Mutation Negative | EGFR Mutation Positive | p Value | Grade | EGFR Mutation Negative | EGFR Mutation Positive | p Value |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | I and IIN = 52 (%) | 21 (40.4) | 31 (59.6) | <ROWSPAN=2> 0.10 * | I and IIN = 65 (%) | 54 (83.1) | 11 (16.9) | <ROWSPAN=2> 0.005 ** | I and IIN = 22 (%) | 10 (45.5) | 12 (54.5) | <ROWSPAN=2> 0.07 ** |
 | II–III and IIIN = 21 (%) | 13 (61.9) |

[Assistant] 8 (38.1) | II–III and IIIN = 56 (%) | 55 (98.2) | 1 (1.8) | II–III and IIIN = 13 (%) | 10 (76.9) | 3 (23.1) | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | <ROWSPAN=2> Variable | <COLSPAN=4> Infectious species | <ROWSPAN=2> P value |
 | P. falciparum |  | P. vivax |  |
 | --- | --- | --- | --- | --- | --- |
 | Days of symptoms prior to diagnosis | N = 53 |  | N = 100 |  |  |
 | Median [IQR] | 4 | [3-7] | 6 | [4-9] | 0,0326 |
 | Hospitalization (%) | 35/67 | (52) | 30/151 | (20) | <0,0001 |
 | Days of hospitalization | N = 35 |  | N = 29 |  |  |
 | Median [IQR] | 4 | [2-6] | 3 | [2-4] | 0,1701 |
 | Days since return from endemic area | N = 40 |  | N = 59 |  |  |
 | Median [IQR] | 10 | [5-14] | 15 | [8-25] | 0,0078 |
 | Months in endemic area* | N = 29 |  | N = 57 |  |  |
 | Median [IQR] | 1 | [0,6-4,5] | 1 | [0,5-2,5] | 0,2136 |
 | Referred fever (%) | 61/67 | (91) | 125/151 | (83) | 0,1465 |
 | Referred shivers (%) | 29/67 | (43) | 73/151 | (48) | 0,5569 |
 | Referred headache (%) | 45/67 | (67) | 80/151 | (53) | 0,0550 |
 | Referred myalgia (%) | 33/67 | (49) | 69/151 | (46) | 0,6607 |
 | Arthralgia (%) | 10/11 | (91) | 22/32 | (69) | 0,2370 |
 | Vomiting (%) | 25/36 | (69) | 24/44 | (55) | 0,2488 |

[Assistant]
| Sweating (%) | 10/14 | (71) | 17/28 | (61) | 0,7337 |
 | Tachypnea (%) | 9/18 | (50) | 5/12 | (42) | 0,7220 |
 | Jaundice (%) | 22/34 | (65) | 19/46 | (41) | 0,0448 |
 | Splenomegaly (%) | 22/43 | (51) | 20/58 | (34) | 0,1060 | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> | Groups | Genotype | Tail intensity mean ± SD |
 | --- | --- | --- |
 | <ROWSPAN=2> Non-diabetic | GG (n = 35) | 38.6 ± 17.0 |
 | GA (n = 04) | 36.06 ± 20.2 |
 | <ROWSPAN=2>

[Assistant]
MGH | GG (n = 21) | 38.32 ± 13.5 |
 | GA (n = 03) | 30.16 ± 11.6 |
 | <ROWSPAN=2> Diabetic | GG (n = 40) | 34.7 ± 11.3 |
 | GA (n = 07) | 43.3 ± 13.3 | </md>


[User]
<|image|>Continue parse the table with markdown style: <md> | Sample name | Pg | IDT (°C) | FDT (°C) | <COLSPAN=3> DT (°C) at every 20% weight loss | Residual left (%) |
 |  |  |  |  | 20 | 40 | 60 |  |
 | --- | --- | --- |

[Assistant]
--- | --- | --- | --- | --- |
 | Raw fiber | – | 241.18 | 356.38 | 287.74 | 326.35 | 348.77 | 18.93 |
 | Delignified fiber | – | 250.13 | 375.39 | 302.45 | 348.31 | 368.13 | 18.03 |
 | dGo-g-poly(MMA) | 26.54 | 261.13 | 432.18 | 294.11 | 333.62 | 401.11 | 13.84 |
 | dGo-g-poly(MMA-co-EMA) | 51.56 | 270.23 | 490.24 | 304.45 | 345.65 | 413.43 | 7.63 |
 | dGo-g-poly(MMA-co-EA) | 86.32 | 273.63 | 523.52 | 325.54 | 357.84 | 434.84 | 4.57 | </md>


[User] <|image|>Render the image in Markdown format.

[Assistant]
<md> |  | <COLSPAN=2> With a history of cancer | <COLSPAN=2> Without a history of cancer |
 | --- | --- | --- | --- | --- |
 |  | N | % | N | % |
 | Total N | 855 | 100.0 | 2814 | 100.0 |
 | Age (y) at diagnosisb | <COLSPAN=2>  | <COLSPAN=2>  |
 | Mean (SD) | <COLSPAN=2> 67.9 (12.9) | <COLSPAN=2> 63.3 (15.4) |
 | Median (range) | <COLSPAN=2> 69 (27–96) | <COLSPAN=2> 64 (19–103) |
 | Male | 425 | 49.7 | 1540 | 54.7 |
 | Born in Denmark | 836 | 97.8 | 2727 | 96.9 |
 | Site of metastasisb |  |  |  |  |
 | Skin | 289 | 33.8 | 1527 | 54.3 |
 | Soft tissue | 36 | 4.2 | 166 | 5.9 |
 | Liver | 215 | 25.1 | 115 | 4.1 |
 | Lung | 35 | 4.1 | 89 | 3.2 |
 | GI Tract | 38 | 4.4 | 64 | 2.3 |
 | Brain | 35 | 4.1 | 59 | 2.1 |
 | Bone | 16 | 1.9 | 39 | 1.4 |
 | Salivary gland | 12 | 1.4 | 34 | 1.2 |
 | Mamma | 10 | 1.2 | 28 | 1.0 |
 | Cytology, pleura | 4 | 0.5 | 17 | 0.6 |
 | Mucous membrane | 6 | 0.7 | 6 | 0.2 |
 | Gallbladder/Pancreas | 2 | 0.2 | 5 | 0.2 |
 | Vulva | 4 | 0.5 | 5 | 0.2 |
 | Unspecified or unknown | 153 | 17.9 | 660 | 23.5 |
 | Deathb | 749 | 87.6 | 2093 | 74.4 |
 | Time (mo) to deathb, Median (range) | <COLSPAN=2> 5.7 (0–156) | <COLSPAN=2> 9.7 (0–176) | </md>


[User] <|image|>Render the illustration in Markdown format.

[Assistant]
<md> | Probability level | Number of correctly predicted events | Number of correctly predicted nonevents | Number of nonevents predicted as events | Number of events predicted as nonevents | Sensitivity | Specificity | PCR |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | 0.983 | 65 | 570 | 1 | 597 | 0.098 | 0.998 | 0.138 |
 | 0.970 | 66 | 570 | 1 | 596 | 0.100 | 0.998 | 0.128 |
 | 0.909 | 66 | 569 | 2 | 596 | 0.100 | 0.996 | 0.108 |
 | 0.847 | 552 | 519 | 52 | 110 | 0.834 | 0.909 | 0.098 |
 | 0.754 | 579 | 493 | 78 | 83 | 0.875 | 0.863 | 0.088 |
 | 0.628 | 604 | 458 | 113 | 58 | 0.912 | 0.802 | 0.078 |
 | 0.340 | 634 | 385 | 186 | 28 | 0.958 | 0.674 | 0.058 | </md>


[User] <|image|>Convert the picture into Markdown language.

[Assistant]
<md> | <ROWSPAN=2> Serial number | <ROWSPAN=2> Author name/date | <ROWSPAN=2> Scale | N | Baseline mean age | Males (% of patients) |
 | (CABG/PCI) | (CABG/PCI) | (CABG/PCI) |
 | --- | --- | --- | --- | --- | --- |
 | 1 | Zhang et al., 2003 [11] | SAQ | 500/488 | 61.4/61.4 | 79.0/79.0 |
 | 2 | Spertus et al., 2005 [12] | SAQ | 432/1027 | 66.0/66.1 | 74.0/70.0 |
 | 3 | Borkon et al., 2002 [13] | SAQ | 223/252 | 67.0/64.0 | 66.0/68.0 |
 | 4 | Abdallah et al., 2013 [14] | SAQ | 947/953 | 63.0/63.2 | 69.8/73.2 |
 | 5 | Cohen et al., 2011 [15] | SAQ and SF-36 | 897/903 | 65.0/65.2 | 78.9/76.4 |
 | 6 | van Domburg et al., 2008 [16] | SF-36 | 492/483 | 62.0/61.0 | 77.0/77.0 |
 | 7 | Rumsfeld et al., 2003 [17] | SF-36 | 196/193 | 67.3/67.6 | 98.5/98.9 |
 | 8 | Szygula-Jurkiewicz et al., 2005 [18] | Sf-36 | 104/392 | 62.4/61.8 | 71.2/66.3 |
 | 9 | Favarato et al., 2007 [19] | Sf-36 | 175/180 | 59.0/59.0 | 53.0/40.0 |
 | 10 | Währborg 1999 [2] | The Nottingham Health Profile | 154 | — | — |
 | 11 | Pocock et al., 1996 [20] | Nottingham Health Profile | 1011 | — | — |
 | 12 | Brorsson et al., 2001 [1] | Swedish Quality of Life Survey | 252/349 | 62.8/59.8 | 77.8/75.1 |
 | 13 | Serruys et al., 2001 [8] | EuroQOL questionnaire | 579/593 | 61.0/61.0 | 76.0/77.0 | </md>


[User] <|image|>Convert the photo into Markdown format.

[Assistant]
<md> |  | <COLSPAN=3> Sampling method |  |
 | Species | <COLSPAN=2> Human Landing Catchesa | Pyrethrum Spray | Total |
 |  | Indoors | Outdoors | Collectionb |  |
 | --- | --- | --- | --- | --- |
 | An. gambiae sl | 4,262 | 3,101 | 1,611 | 8,974 |
 | An. pharoensis | 849 | 947 | 48 | 1,844 |
 | An. funestus | 156 | 62 | 286 | 504 |
 | An. ziemanni | 71 | 120 | 1 | 192 |
 | An. rufipes | 6 | 4 | 136 | 146 |
 | An. wellcomei | 8 | 7 | 0 | 15 |
 | An. squamosus | 2 | 4 | 0 | 6 |
 | An. nili | 4 | 1 | 0 | 5 |
 | An. coustani | 0 | 2 | 0 | 2 |
 | Total | 5,358 | 4,248 | 2,082 | 11,688 | </md>


[User] <|image|>Convert the diagram to Markdown syntax.

[Assistant]
<md> | <ROWSPAN=2>  | <COLSPAN=2> BOYS | <COLSPAN=2> GIRLS | <COLSPAN=2> Kruskal Wallis |
 | F | % | F | % | H | p |
 | --- | --- | --- | --- | --- | --- | --- |
 | Marihuana |  |  |  |  |  |  |
 | Never (1) | 361 | 82.99 | 559 | 93.63 |  |  |
 | Ever tried (2) | 31 | 7.13 | 14 | 2.35 |  |  |
 | Once or twice (3) | 12 | 2.76 | 2 | 0.34 |  |  |
 | 3-5 times (4) | 2 | 0.46 | - | - |  |  |
 | 6-9 times (5) | 4 | 0.92 | 4 | 0.67 |  |  |
 | 20-39 times (6) | - | - | 2 | 0.34 |  |  |
 | 40 and more (7) | 12 | 2.76 | 1 | 0.17 |  |  |
 | Missing | 13 | 2.99 | 15 | 2.51 | 35.47 | 0.001 |
 | Hashish |  |  |  |  |  |  |
 | Never (1) | 399 | 91.72 | 580 | 97.15 |  |  |
 | Ever tried (2) | 7 | 1.61 | 1 | 0.17 |  |  |
 | Once or twice (3) | 3 | 0.69 | 1 | 0.17 |  |  |
 | 3-5 times (4) | 1 | 0.23 | - | - |  |  |
 | 6-9 times (5) | 3 | 0.69 | 2 | 0.34 |  |  |
 | 20-39 times (6) | - | - | - | - |  |  |
 | 40 and more (7) | 6 | 1.38 | - | - |  |  |
 | Missing | 16 | 3.68 | 13 | 2.18 | 17.46 | 0.001 |
 | LSD |  |  |  |  |  |  |
 | Never (1) | 410 | 94.25 | 580 | 97.15 |  |  |
 | Ever tried (2) | 3 | 0.69 | - | - |  |  |
 | Once or twice (3) | - | - | - | - |  |  |
 | 3-5 times (4) | - | - | - | - |  |  |
 | 6-9 times (5) | 3 | 0.69 | 1 | 0.17 |  |  |
 | 20-39 times (6) | 1 | 0.23 | - | - |  |  |
 | 40 and more (7) | 5 | 1.15 | - | - |  |  |
 | Missing | 13 | 2.99 | 16 | 2.68 | 13.65 | 0.001 | </md>


[User] <|image|>Transform the photo into Markdown format.

[Assistant]
<md> |  | CD86 | CD83 | HLA-DR | n |
 | --- | --- | --- | --- | --- |
 | Im-DC | 15737 ± 7681 *** | 1316 ± 673 *** | 39405 ± 33712 ** | 15 |
 | Mat-DC | 22704 ± 13632 | 4371 ± 3189 | 70692 ± 66038 | 15 |
 | Dexa-DC | 12291 ± 11364 *** | 2811 ± 2343 * | 50928 ± 62830 | 11 |
 | Rapa-DC | 23782 ± 10961 | 4785 ± 2786 | 75297 ± 56014 | 15 |
 | VitD3-DC | 6398 ± 6243 ** | 1941 ± 3096 ** | 20851 ± 38803 ** | 11 | </md>


[User]
<|image|>Continue parse the photo with markdown style: <md> | Peak acceleration | ICC (95%) |
 | --- | ---

[Assistant]
|
 | AM maximum | 0.952 (0.925–0.970) |
 | AM minimum | 0.877 (0.805–0.922) |
 | ML maximum | 0.967 (0.947–0.979) |
 | ML minimum | 0.966 (0.946–0.978) |
 | V maximum | 0.987 (0.980–0.992) |
 | V minimum | 0.819 (0.714–0.886) |
 | AP maximum | 0.970 (0.952–0.981) |
 | AP minimum | 0.968 (0.950–0.980) | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> |  | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 |
 | --- | --- | --- | --- | --- | --- |
 | Mass media (total) |  |  |  |  |  |
 | Not at all | 2.94 (1.95–4.46) | 3.06 (1.99–4.73) | 2.98 (1.92–4.63) | 2.53 (1.62–3.94) | 1.85 (1.17–2.91) |
 | Occasionally | 1.76 (1.34–2.30) | 1.72 (1.30–2.27) | 1.68 (1.27–2.22) | 1.50 (1.14–1.99) | 1.21 (0.90–1.61) |
 | Moderate exposure | 1.30 (1.01–1.68) | 1.25 (0.96–1.62) | 1.21 (0.93–1.58) | 1.09 (0.84–1.43) | 0.90 (0.69–1.19) |
 | Very frequent but not daily | 1.12 (0.91–1.34) | 1.14 (0.92–1.40) | 1.13 (0.91–1.39) | 1.08 (0.87–1.34) | 0.97 (0.78–1.20) |
 | Daily | Ref | Ref | Ref | Ref | Ref |
 | Age |  |  |  |  |  |
 | 15–19 | 1.19 (1.01–1.40) | 1.17 (0.99–1.38) | 1.17 (0.99–1.39) | 1.17 (0.99–1.38) | 1.06 (0.89–1.26) |
 | 20–24 | Ref | Ref | Ref | Ref | Ref |
 | Area of residence |  |

[Assistant]
 |  |  |  |
 | Rural |  |  |  | 1.61 (1.34–1.93) | 1.40 (1.15–1.68) |
 | Urban |  |  |  | Ref | Ref |
 | Formal education |  |  |  |  |  |
 | No education |  |  |  |  | 3.67 (2.30–5.85) |
 | Basic education |  |  |  |  | 2.23 (1.84–2.71) |
 | Secondary + |  |  |  |  | Ref | </md>


[User]
<|image|>Parse the picture content behind with markdown code: <md> | Group | Maternal plasma (ng/ml) | Offspring’s plasma (ng/ml) | Placenta (pg/mg tissue) |
 | --- | --- | --- | --- |
 | control | 142.1 ± 15.5 | 115.9 ± 5.1 | 79.7 ± 5.2 |
 | Cd2+0.5 | 231.1 ±

[Assistant] 12.9* | 168.9 ± 9.4* | 143.4 ± 11.0* | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | Any resistance gene present | <COLSPAN=2> Phenotypic susceptibility to CL |
 |  | Resistant | Sensitive |
 | --- | --- | --- |
 | Positive (n:134) | 80 | 54 |
 | Negative (n:166) | 29 | 137 |
 | Total (n:300) | 109 | 191 | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | SNP_ID | 1st-PCRP | 2nd-PCRP | UEP_SEQ |
 | --- | --- | --- | --- |
 | rs2285332 | ACGTTGGATGTGAGCTGC TTCAGTGTAACC | ACGTTGGATGCTTTG CCAAAAGCTAAGCAG | gGCCAAAAGCTAAGCAGTGGTGAA |
 | rs701848 | ACGTTGGATGATAGTGCTC CCCCGAGTTG | ACGTTGGATGCTCCG CTTAAAATCGTATGC | TGATTTTTTTTAAGAAGTGAAATTGA |
 | rs11202607 | ACGTTGGATGTATTTATG ACCTGGCCCTCC | ACGTTGGATGTTACAA TTTCGGGCACCGCA | cTTCGGGCACCGCATATTAAAA |
 | rs680413 | ACGTTGGATGCCTAGA CCTAGTCTCCTTGC | ACGTTGGATGGGGAG AGATGACTGAGTTAG | ggTGACTGAGTTAGATGAGAC |
 |

[Assistant]
rs512715 | ACGTTGGATGAACAG CCACTCGGCTTACTG | ACGTTGGATGCCCTT CTTCCTCCCTTTAAC | AACTTATCCATTCACTTAAAACATTA |
 | rs1133822 | ACGTTGGATGCCTTC GTTCTCCTTCGTTTG | ACGTTGGATGTTTC TCTGCTCTGGCAGACC | gGGGCACCACTTGTCACGG |
 | rs4777498 | ACGTTGGATGGGATTG TGGATTGTGGGTTC | ACGTTGGATGTGAG GTCTAGGCTCACATGC | GCTCACATGCAGGTAAT |
 | rs3094 | ACGTTGGATGGATTATC GCGAGTGGTTGAC | ACGTTGGATGAATGAG CTGAGGAGACAGAG | ccGCTGAGGAGACAGAGCCTGGG |
 | rs8004334 | ACGTTGGATGACTAAA GGCCTCCCAAGTCA | ACGTTGGATGTCCTA CTGGGCCTTTGCTTC | aTTTGCTTCCCCCACAAATTAAAT |
 | rs3733839 | ACGTTGGATGCCATGC AACCAATTCCATCC | ACGTTGGATGGTCTCC TGACTTGTCAAGGC | TCCTCTGCACCTGTCCT | </md>


[User]
<|image|>What are the following table content in markdown style: <md> | Null simulation model | Empirical FWER atα= 0.05level |
 | --- | --- |
 | Copy number data | 0.0488 |
 | Clumped copy number data (25%) | 0.0500 |
 | Clumped copy number data (50%) | 0.0493 |

[Assistant] | Clumped copy number data (75%) | 0.0505 | </md>


[User] <|image|>Convert the table into Markdown format.

[Assistant]
<md> | Variable | <COLSPAN=5> Statistic |
 |  | N | Min. | Max. | Mean | SD |
 | --- | --- | --- | --- | --- | --- |
 | Achievement | 121 | 68 | 118 | 103.88 | 11.43 |
 | Procedural skill | 121 | 5.00 | 12.00 | 10.84 | 1.44 |
 | Self-efficacy | 121 | 1.00 | 7.00 | 5.34 | 1.19 |
 | UFC | 121 | 4.00 | 7.00 | 5.98 | 0.75 |
 | Potential flexibility | 121 | 0.00 | 12.00 | 8.79 | 3.35 |
 | Practical flexibility | 121 | 0.00 | 12.00 | 6.31 | 3.99 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Cattle | Pigs |
 | --- | --- |
 | <ROWSPAN=5> Cow (female) 73 | Soar (female) 135 (10 piglets) |
 | Large white 65 |
 | Large black 10 |
 | Hampshire 45 |
 | Duroc 15 |

[Assistant] | Bull (male) 127 | Boar (male) 15 | </md>


[User] <|image|>Transcribe the diagram into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Follow-up visits | <COLSPAN=4> Group A (OLO) | <COLSPAN=4> Group B (MMC) |
 | Subgroup (I) | Subgroup (II) | Subgroup (III) | Subgroup (IV) | Subgroup (I) | Subgroup (II) | Subgroup (III) | Subgroup (IV) | P value |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1st week | 12 (80%) | 1 (6.7%) | 2 (13.3%) | 0 (0.0%) | 14 (93.3%) | 0 (0.0%) | 1 (6.7%) | 0 (0.0%) | 0.399 |
 | 2nd week | 12 (80%) | 1 (6.7%) | 2 (13.3%) | 0 (0.0%) | 13 (86.7%) | 1 (6.7%) | 1 (6.7%) | 0 (0.0%) | 0.35 |
 | 1st month | 12 (80%) | 1 (6.7%) | 2 (13.3%) | 0 (0.0%) | 12 (80%) | 2 (13.3%) | 0 (0.0%) | 1 (6.7%) | 0.85 |
 | 2nd month | 10 (66.7%) | 3 (20%) | 1 (6.7%) | 1 (6.7%) | 8 (53.3%) | 3 (20%) | 1 (6.7%) | 1 (6.7%) | 0.523 |
 | 4th month | 8 (53.3%) | 4 (26.7%) | 2 (13.3%) | 1 (6.7%) | 9 (60%) | 4 (26.7%) | 1 (6.7%) | 1 (6.7%) | 0.511 |
 | 6th month | 9 (60%) | 2 (13.3%) | 3 (20%) | 1 (6.7%) | 5 (33.3%) | 5 (33.3%) | 4 (26.7%) | 1 (6.7%) | 0.323 |
 | 9th month | 8 (53.3%) | 4 (26.7%) | 2 (13.3%) | 1 (6.7%) | 5 (33.3%) | 4 (26.7%) | 4 (26.7%) | 2 (13.3%) | 0.263 |
 | 12th month | 8 (53.3%) | 3 (20%) | 2 (13.3%) | 2 (13.3%) | 7 (46.7%) | 3 (20%) | 3 (20%) | 2 (13.3%) | 0.471 | </md>


[User] <|image|>Transform the image into Markdown format.

[Assistant]
<md> | BIS variable | ICC (95% CI) | BIS trial number* | BIS measure coefficient (95% CI) | p value |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> R0 | <ROWSPAN=2> 0.999 (0.999–0.999) | 2 | −0.07 (− 0.68–0.54) | 0.83 |
 | 3 | − 0.06 (− 0.68–0.55) | 0.84 |
 | <ROWSPAN=2> Ri | <ROWSPAN=2> 0.999 (0.998–0.999) | 2 | 0.41 (− 1.90–2.71) | 0.73 |
 | 3 | 2.06 (− 0.24–4.37) | 0.80 |
 | <ROWSPAN=2> Rinf | <ROWSPAN=2> 0.9996(0.999–0.999) | 2 | 0.01 (− 0.30–0.32) | 0.94 |
 | 3 | 0.07 (− 0.24–0.38) | 0.66 |
 | <ROWSPAN=2> ECF | <ROWSPAN=2> 0.999 (0.998–0.999) | 2 | 0.03 (− 0.17–0.22) | 0.78 |
 | 3 | 0.12 (− 0.07–0.32) | 0.22 |
 | <ROWSPAN=2> ICF | <ROWSPAN=2> 0.997 (0.996–0.998) | 2 | − 0.12 (− 0.46–0.22) | 0.49 |
 | 3 | − 0.26 (− 0.61–0.08) | 0.13 |
 | <ROWSPAN=2> TBF | <ROWSPAN=2> 0.999 (0.999–0.999) | 2 | − 0.09 (− 0.38–0.20) | 0.53 |
 | 3 | − 0.14 (− 0.43–0.15) | 0.33 | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> |  | <COLSPAN=2> COPD-related cost | <COLSPAN=2> Total health care cost |
 | <ROWSPAN=3> Variables | Adjusted regression | <ROWSPAN=3> p-value | Adjusted regression | <ROWSPAN=3> p-value |
 | coefficient | coefficient |
 | [95% confidence limits] | [95% confidence limits] |
 | --- | --- | --- | --- | --- |
 | Hospitalizations | 0.988 [0.926, 1.050] | <0.001 | 0.609 [0.543, 0.674] | <0.001 |
 | Clinic visits | 0.053 [0.040, 0.067] | <0.001 | 0.027

[Assistant]
[0.015, 0.039] | <0.001 |
 | Treated by a pulmonologist | 0.299 [0.133, 0.464] | <0.001 | 0.208 [0.053, 0.363] | 0.009 |
 | Number of medications | 0.012 [0.003, 0.021] | 0.011 |  | NS |
 | FEV1 | −0.133 [−0.234, -0.031] | 0.011 |  | NS |
 | Short acting anti-muscarinic | 0.246 [0.100, 0.393] | 0.001 |  | NS |
 | BMI | −0.012 [−0.023, -0.001] | 0.025 |  | NS |
 | Inhaled corticosteroid | 0.168 [0.005, 0.331] | 0.043 |  | NS |
 | DM |  | NS | 0.291 [0.134, 0.449] | <0.001 |
 | Depression |  | NS | 0.195 [0.040, 0.351] | 0.014 |
 | Age |  | NS | −0.008 [−0.014, -0.002] | 0.012 |
 | Nursing home resident |  | NS | 0.506 [0.104, 0.909] | 0.014 |
 | Maximum serum bicarbonate |  | NS | 0.021 [0.003, 0.039] | 0.026 | </md>


[User] <|image|>Convert the illustration into Markdown format.

[Assistant]
<md> | Intermodal relationship | N | Robust | Out | Control |
 | --- | --- | --- | --- | --- |
 | <COLSPAN=5> A. PFC GABA: PFC BOLD |
 | No-Think | 23 | −0.02 | 1 | 0.26 |
 | Think | 23 | −0.05 | 1 | 0.27 |
 | <COLSPAN=5> B. PFC GABA: behavior |
 | SIF | 23 | −0.04 | 1 | −0.23 |
 | <COLSPAN=5> C. PFC GABA: PPI |
 | DLPFC | 23 | 0.04 | 0 | −0.20 |
 | <COLSPAN=5> D. VIS GABA: VIS BOLD |
 | No-Think | 20 | −0.42* | 1 | −0.31 |
 | Think | 20 | −0.43* | 0 | −0.31 |
 | <COLSPAN=5> E. VIS GABA: Behavior |
 | SIF | 20 | 0.32 | 3 | 0.25 |
 | <COLSPAN=5> F. VIS GABA: PPI |
 | DLPFC | 20 | 0.12 | 0 | 0.27 | </md>


[User]
<|image|>Parse the diagram content behind with markdown code: <md> |  | Primary antibody | Secondary antibody |
 | --- | --- | --- |
 | Type II collagen (COL II) | Mouse anti-COL II, monoclonal, II-II6B3, DSHB | Biotinylated horse anti-mouse IgG, rat adsorbed, BA-2001, Vector

[Assistant]
|
 | Type X collagen (COL X) | Mouse anti-COL X, monoclonal, 2031501001, Quartett, GE | The same as above |
 | Type I collagen (COL I) | Mouse anti-COL II, C2456, Sigma-Aldrich, ascites fluid | The same as above |
 | Aggrecan | Rabbit polyclonal to aggrecan, ab36861, abcam | Biotinylated horse anti-rabbit IgG, BA-1100, Vector |
 | Type VI collagen (COL VI) | Rabbit polyclonal to COL VI (Biotin), ab6583, abcam | None | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> |  | % Bellow of EAR ( n = 189) |
 | --- | --- |
 | Unadjusted FFQ |  |
 | Vitamin

[Assistant]
B2 | 4.00 |
 | Vitamin B6 | 14.86 |
 | Vitamin B12 | 7.00 |
 | Folate | 11.00 |
 | Calibrated FFQ |  |
 | Vitamin B2 | 0.00 |
 | Vitamin B6 | 20.18 |
 | Vitamin B12 | 0.10 |
 | Folate | 0.10 | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | R&D awareness | <COLSPAN=3> Occasion I (n = 599) | <COLSPAN=3> Occasion II (n = 526) |
 | <ROWSPAN=2>  | DCP | PCP | p-value | DCP | PCP | p-value |
 | (n) | (n) |  | (n) | (n) |  |
 | --- | --- | --- | --- | --- | --- | --- |
 | Acquired knowledge | 96 | 98 | NS | 95 | 95 | NS |
 | Became interested | 76 | 55 | <

[Assistant]
0.05 | 80 | 66 | < 0.05 |
 | New way of thinking | 53 | 84 | NS | 52 | 60 | NS |
 | Willingness to change | 24 | 37 | < 0.05 | 32 | 33 | NS | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | Factor | Hazard Ratio | 95% Confidence Interval | P-value for inclusion |
 | --- | --- | --- | --- |
 | CD133 | 1.611 | 1.197 – 2.170 | 0.002 |
 | VEGFa |

[Assistant] 1.692 | 1.257 – 2.277 | 0.001 | </md>


[User] <|image|>Encode the table in Markdown syntax.

[Assistant]
<md> | The TESS | ICC (95 % CI)a | Cronbach’s α | Correlationb |
 | --- | --- | --- | --- |
 | Lower extremity | 0.893 (0.755–0.937) | 0.953 | 0.533–0.869 |
 | Upper extremity | 0.932 (0.745–0.971) | 0.921 | 0.587–0.913 | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> |  | <COLSPAN=3> Baseline | <COLSPAN=3> Follow-up |
 |  | R2 | Adjusted mean difference | P | R2 | Adjusted mean difference | P |
 | --- | --- | --- | --- | --- | --- | --- |
 | n |  | 69 |  |  | 69 |  |
 | Total AT | 0.58 | −0.075 (−0.154, 0.001) | 0.05 | 0.63 | −0.193 (−0.312, −0.074) | 0.002 |
 | Superficial subcutaneous abdominal AT | 0.48 | −0.018 (−0.033, −0.002) | 0.02 | 0.44 | −0.039 (−0.070, −0.007) | 0.02 |
 | Superficial subcutaneous non-abdominal AT | 0.59 | −0.046 (−0.100, 0.008) | 0.09 | 0.64 | −0.124 (−0.205, −0.043) | 0.003 |
 | Deep subcutaneous abdominal AT | 0.43 |

[Assistant]
−0.002 (−0.004, 0.001) | 0.23 | 0.25 | −0.007 (−0.014, −0.001) | 0.04 |
 | Deep subcutaneous non-abdominal AT | 0.23 | −0.002 (−0.003, 0.000) | 0.10 | *0.22 | −9.6%*(−26.1%, 10.6%) | 0.32** |
 | Internal abdominal AT | 0.10 | −0.001 (0.004, 0.003) | 0.77 | 0.01 | −0.001 (−0.009, 0.006) | 0.69 |
 | Internal non-abdominal AT | 0.33 | −0.007 (−0.015, 0.001) | 0.07 | 0.40 | −0.019 (−0.032, −0.005) | 0.007 |
 | Ratio (IA/SCA)0.6 | 0.02 | 0.01 (−0.01, 0.02) | 0.37 | 0.07 | 0.01 (−0.01, 0.02) | 0.38 |
 | n |  | 54 |  |  | 54 |  |
 | IHCL | 0.02* | −6.4% (−39.7%, 45.2%)* | 0.76** | 0.04* | −31.3% (−60.7%, 20.1%)* | 0.18** | </md>


[User] <|image|>Convert the photo into Markdown format.

[Assistant]
<md> | Ministry | Programmes/initiative | Bastar | Koraput | West Singhbhum |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Ministry of Rural Development | NRLM Aajeevika | √ | √ | √ |
 | Integrated Watershed Management Projects | √ | √ | √ |
 | Ministry of Tribal Affairs | ITDA | – | √a | – |
 | Ministry of Women and Child Development | ICDS | √ | √ | √ |
 |  | Mission Shakti | - | √ | - |
 | Ministry of Food and Civil Supplies | PDS | √ | √ | √ |
 | Ministry of Finance | NABARD, SHG-Bank linkage programme, Farmers clubs | √ | √ | √ |
 | Ministry of Health and Family Welfare | NRHM, Village Heath and Sanitation Committees | √ | √ | √ |
 | Ministry of Human Resource Development | Sarv Sikhsha Abhiyaan | √ | √ | √ |
 | Ministry of Environment, Forest and Climate Change | Forest conservation/Integrated Wildlife Management | √ | √ | √ | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> | <ROWSPAN=2>  | <ROWSPAN=2> Javanese Surinamese (n = 197) | <ROWSPAN=2> South-Asian Surinamese (n = 2738) | <COLSPAN=2> Differences between ethnic groups Adjusted for age and sex: Javanese Surinamese were taken as a reference group |
 | OR | 95% CI |
 | --- | --- | --- | --- | --- |
 | Overweight based on BMI (%) | 39.1 | 38.4 | 0.95 | 0.70–1.27 |
 | Obesity based on BMI (%) | 32.5 | 37.7 | 1.31 | 0.95–1.78 |
 | Obesity based on high waist circumference (%) | 56.9** | 70.1 | 2.20 | 1.60–3.02 |
 | Obesity based on high waist-to-hip Ratio (%) | 74.6** | 83.8 | 2.44 | 1.66–3.57 |
 | CVD according to Rose | 7.7** | 17.2 | 2.55 | 1.48–4.35 |
 | Diabetes | 8.2** | 18.7 | 2.77 | 1.67–4.60 |
 | Hypertension | 37.8 | 42.4 | 1.28 | 0.91–1.79 |
 | High total cholesterol | 41.1 | 39.5 | 0.94 | 0.70–1.26 |
 | High LDL | 32.8 | 36.9 | 1.18 | 0.86–1.62 |
 | Low HDL | 26.9** | 41.2 | 1.89 | 1.34–2.65 |
 | High triglycerides | 13.7 | 9.6 | 0.64 | 0.41–0.99 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> | Treatment (Dose) | Efficacy | Reference |
 | --- | --- | --- |
 | Iodoquinole (650 mg t.i.d) | 0% | [91] |
 | Emetine (100 μg/ml) | 50% | [92] |
 | Metronidazole (2000 mg s.i.d) | 0% | [93] |
 | Metronidazole (1500 mg s.i.d) | 100% | [26] |
 | Metronidazole (750 mg t.i.d) | 100% | [24] |
 | Metronidazole (750 mg t.i.d) | 100% | [21] |
 | Metronidazole (500 mg t.i.d) | 100% | [79] |
 | Metronidazole (250- 750 mg t.i.d) | 33% | [80] |
 | Metronidazole (750 mg t.i.d) | 100% | [81] |
 | Metronidazole (1500 mg s.i.d) | 80% | [94] |
 | Metronidazole (800 mg t.i.d) | 0% | [30] |
 | Metronidazole (30 mg/kg twice daily) | 67% | [89] |
 | Nitazoxanide (500 mg t.i.d) | 100% | [86] |
 | Nitazoxanide (100-200 mg b.i.d

[Assistant]
for children <12 yr, 500 mg b.i.d for >11 yr) | 86% | [88] |
 | Nitazoxanide (500 mg t.i.d) | 100% | [95] |
 | Ornidazole (500 mg t.i.d) | 50% | [96] |
 | Paromomycin (25 mg/kg t.i.d) | 100% | [93] |
 | Paromomycin (500 mg t.i.d) | 100% | [97] |
 | Paromomycin (25 mg/kg t.i.d) | 100% | [82] |
 | Paromomycin (1000 mg b.i.d) & MZ (750 mg t.i.d) | 100% | [25] |
 | Saccharomyces boulardii (250 mg b.i.d) | 78% | [89] |
 | Trimethroprim-SMX | 22% | [80] |
 | Trimethroprim-SMX (6 mg/kg TMP, 30 mg/kg SMX s.i.d) | 95% | [98] |
 | Trimethropim- SMX (320 mg TMP, 1600 mg SMX s.i.d) | 93% | [98] |
 | Trimethroprim- SMX (80 mg TMP, 400 mg SMX t.i.d) | 100% | [30] |
 | Triple therapy (nitazoxanide, furazolidone and secnidazole) | 0% | [90] | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> | Curve characters | Values |
 | --- | --- |
 | Regression equation | y = 0.005 x |
 | R2 | 0.988 |
 | RF stDev | 0.00057 |
 | RF % RSD | 10.563 |
 | Average RF | 0.0054 |
 | Detection limit(μ/ml-1, S/N =5) | 0.02 | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> | Condition | Km, ATP (μM) | IC50, NaPP1 (nM) |
 | --- | --- | --- |
 | mHck alone | 12.1 ± 2.0 | > 1,000 |
 | mHck + Nef-SF2 | 14.8 ± 1.4 | > 1,000 |
 | mHck-TA alone | 62 ± 12.6 | 53.3 ± 8.2 |
 | mHck-TA + Nef-SF2 | 68 ± 10.7 | 47.4 ± 6.0 |
 | mHck-TA + Nef-Consensus | 84 ± 3.5 | 37.6 ± 4.6 |
 | mHck-HART alone | 105.2 ± 29.0 | n.d. |
 | mHck-HART + Nef-SF2 | 49.34 ± 5.8 | n.d. |
 | mHck-TA-HART alone | 181 ± 28.7 | 8.5 ± 0.7 |
 | mHck-TA-HART + Nef-SF2 | 69 ± 17.6 | 2.4 ± 0.3 |
 | mHck-TA-HART + Nef-Consensus | 76 ± 23.1 | 3.2 ± 0.2 | </md>


[User] <|image|>Interpret the table as Markdown format.

[Assistant]
<md> | Fat Content Category | Low SES (%) | High SES (%) |
 | --- | --- | --- |
 | Low | 34.4%(n = 11) | 44.8%(n = 13) |
 | Medium | 31.3%(n = 10) | 31.0%(n = 9) |
 | High | 34.4%(n = 11) | 24.1%(n = 7) | </md>


[User] <|image|>Interpret the image as Markdown format.

[Assistant]
<md> | Variables | 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | 11. |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 1. Job demand | 1 |  |  |  |  |  |  |  |  |  |  |
 | 2. Job control | -0.02 | 1 |  |  |  |  |  |  |  |  |  |
 | 3. Social support | -0.11** | 0.26** | 1 |  |  |  |  |  |  |  |  |
 | 4. Stress | 0.21** | 0.01 | -0.21** | 1 |  |  |  |  |  |  |  |
 | 5. Anxiety | 0.18** | 0.04 | -0.14** | 0.79** | 1 |  |  |  |  |  |  |
 | 6. Depression | 0.19** | -0.03 | -0.23** | 0.84** | 0.74** | 1 |  |  |  |  |  |
 | 7. Physical health | -0.08* | 0.09* | 0.25** | -0.41** | -0.40** | -0.39** | 1 |  |  |  |  |
 | 8. Psychological status | -0.02 | 0.09* | 0.20** | -0.22** | -0.19** | -0.27** | 0.45** | 1 |  |  |  |
 | 9. Environment | -0.14** | 0.13** | 0.27** | -0.34** | -0.27** | -0.33** | 0.59** | 0.54** | 1 |  |  |
 | 10. Social relationships | -0.04 | 0.15** | 0.21** | -0.29** | -0.23** | -0.29** | 0.53** | 0.45** | 0.58** | 1 |  |
 | 11. Age | 0.04 | 0.10** | -0.15** | 0.12** | 0.13** | 0.12** | -0.05 | -0.08* | -0.01 | 0.12** | 1 | </md>


[User]
<|image|>Parse the following content of the photo in markdown code: <md> | <ROWSPAN=3-COLSPAN=2>  | <COLSPAN=2> Incidence rate of HIV (per 100,000 inhabitants) |
 | Recife | Curitiba |
 | --- | --- | --- | --- |
 | <ROWSPAN=4> Age group (years) | 13-24 | 58.7 | 60.2 |
 | 25-34 | 78.9 | 74.1 |
 | 35-49 | 57.9 | 33.9 |
 | 50+ | 22.7 | 4.4 |
 | <ROWSPAN=2> Sex | F | 25.2 | 25.1 |
 | M | 87.3 | 59.4 |
 | <ROWSPAN=3> Exposure category | F | 25.2 | 25.1 |
 | MSM | 1,469.0 | 923.7 |
 | Men

[Assistant]
in other exposure categories | 37.2 | 28.1 |
 | <COLSPAN=2> Total (13 years or more) | 53.1 | 41.2 | </md>


[User]
<|image|>What are the following table content in markdown style: <md> |  | <COLSPAN=3> US | CT |
 |  | Trial 1 | Trial 2 | Average |  |
 | --- | --- | --- | --- | --- |
 | 2ndMTH height (mm) | 21.2 ± 2.9 | 20.8 ± 2.8 | 21.0 ± 2.8 | 21.2 ± 2.6 |
 | MS-5thMTH length (mm) | 62.6 ± 3.3 | 62.7 ± 3.3 | 62.7 ± 3.2 | 63.4 ± 2.8 |
 | TAH

[Assistant]
(mm) | 13.4 ± 2.1 | 13.4 ± 2.2 | 13.4 ± 2.1 | 13.1 ± 2.2 |
 | TAI (%) | 21.6 ± 3.5 | 21.4 ± 3.6 | 21.5 ± 3.4 | 20.7 ± 3.6 |
 | SRA (°) | 16.1 ± 8.1 | 16.2 ± 7.1 | 16.1 ± 7.3 | 15.9 ± 8.1 |
 | AUTA (mm2) | 902.0 ± 120 | 891.3 ± 112.7 | 896.7 ± 112.4 | 801.9 ± 111.4 | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | Classification | Mesothelin (nmol/L)Median (min-max) | Midkine (pg/mL)Median (min-max) |
 | --- | --- | --- |
 | <COLSPAN=3> Stage (case number)a |
 | I (12) | 0.95 (0.30-67.50) | 220.54 (103.95-5508.08) |
 | II (11) | 1.20 (0.30-2.80) | 513.61 (103.95-2143.51) |
 | III (34) | 1.25 (0.40-21.50) | 644.89 (103.95-17,381.64) |
 | IV (36) | 2.90 (0.30-27.40) | 925.17 (103.95-5244.74) |
 |  | p = 0.052 | p = 0.059 |
 | <COLSPAN=3> Histology (case number) |
 | Epitheloid (66) |

[Assistant]
2.00 (0.30-67.50) | 623.56 (103.95-17,381.64) |
 | Non-epitheloid (23) | 1.20 (0.30-9.0) | 753.50(103.95-5244.74) |
 | Undefined (6)b | 1.25 (0.60-7.40) | 768.13 (103.95-1722.46) |
 |  | p = 0.033 | p = 0.501 |
 | <COLSPAN=3> Chemotherapy response (case number) |
 | Progressive disease (16) | 1.75 (0.30-67.50) | 731.47 (103.95-5508.08) |
 | Stable disease (17) | 1.70 (0.40-7.70) | 417.94 (103.95-2832.48) |
 | Objective response (12) | 2.70 (0.70-21.50) | 441.06 (103.95-17,381.64) |
 |  | p = 0.452 | p = 0.669 | </md>


[User] <|image|>Encode the image in Markdown syntax.

[Assistant]
<md> |  | Control | MyoKo |
 | --- | --- | --- |
 | <COLSPAN=3> Anatomic indices |
 | Weight (g) | 45.4 ± 1.0 | 46.3 ± 0.6 |
 | Visceral fat (g) | 1.49 ± 0.2 | 0.226 ± 0.02a |
 | Total body fat % | 10.3 ± 1.3 | 4.75 ± 1.1a |
 | Total body lean % | 65.1 ± 1.2 | 71.2 ± 1.1a |
 | Heart weight (mg) | 192 ± 5.5 | 193 ± 2.9 |
 | HW/BW ratio | 0.43 ± 0.01 | 0.42 ± 0.01 |
 | <COLSPAN=3> Plasma characteristics |
 | Fasting glucose (mg/dL) | 114.4 ± 4.5 | 129.8 ± 3.3a |
 | Insulin (μ/L) | 0.38 ± 0.1 | 0.24 ± 0.1 |
 | Triglycerides (mg/dL) | 93.8 ± 8.2 | 84.2 ± 7.7 |
 | Leptin (pg/mL) | 2569 ± 360 | 1602 ± 261a |
 | Cholesterol (mg/dL) | 94.8 ± 3.9 | 131.8 ± 5.3a |
 | <COLSPAN=3> Metabolic indices |
 | Voluntary activity (wheel count, 24 h) | 960.0 ± 310 | 210 ± 67 |
 | Baseline activity (XZY plane, 24 h) | 78578 ± 3908 | 60433 ± 8520 |
 | V02 (mL/kg·h) | 2902 ± 60.8 | 2758 ± 231.0 |
 | Activity (24 h, XY plane from BP) | 4.8 ± 0.9 | 7.2 ± 1.5 | </md>


[User]
<|image|>Parse the following content of the picture in markdown code: <md> | Odorant pairs | Changes | Co-activation | Exclusion (%) | Behaviour |
 | --- | --- | --- | --- | --- |
 | [1] versus [2] | C–>S, polarity and ring size change | 72%/66% | 30 | Habituated |
 | [1] versus [3] | C–>O, polarity, ring size and TPSA changes | 25%/41% | 69 | Dishabituated** |
 | [1] versus [4] | C–>N, polarity and ring TPSA change | 38%/55% | 71 | Dishabituated* |
 | [1] versus [5] | C–>S, C–>N, dipolarity, ring size and TPSA changes | 30%/49% | 55 | — |
 | [1] versus [6] | C–>N (2 × ), ring TPSA changes | 13%/29% | 74 | Dishabituated* |
 | [2] versus [3] | S–>O, polarity and ring TPSA changes | 30%/53% | 62 | — |
 | [2] versus [4] | Polarity, ring size and TPSA changes | 35%/55% | 57 | — |
 | [2] versus [5] | C–>N, dipolarity and ring TPSA change | 37%/65% | 53 | Dishabituated** |
 | [2] versus [6] | Polarity, ring size and TPSA changes | 16%/37% | 81 | — |
 | [3] versus [4]

[Assistant]
| Polarity, ring size change | 43%/38% | 60 | Dishabituated* |
 | [3] versus [5] | O–>N, C–>S, dipolarity | 40%/40% | 60 | — |
 | [3] versus [6] | Ring size and TPSA changes | 23%/30% | 73 | — |
 | [4] versus [5] | C–>S, dipolarity, ring size change | 42%/47% | 55 | Habituated |
 | [4] versus [6] | C–>N, polarity, ring size and TPSA changes | 26%/39% | 68 | — |
 | [5] versus [6] | Dipolarity, ring size and TPSA changes | 33%/44% | 62 | Habituated | </md>


[User]
<|image|>Continue parse the diagram with markdown style: <md> | Health indicator | NFHS 1 (1992-1993) | NFHS 2 (1998-1999) | NFHS 3 (2005-2006) |
 | --- | --- | --- | --- |
 | Any ANC | 94.2 | 98.4 | 98.6 |
 | 3 ANC visits | 18.2 | 91.4

[Assistant]
| 95.9 |
 | ANC given by doctor | 70.6 | 84.3 | 83.6 |
 | ANC given by ANM/nurse-midwife/LHV | 7.5 | 9.8 | 14.3 |
 | ANC given by health worker in the home | 16.1 | 4.4 | 3.3 |
 | Others/dai/none | 5.8 | 1.3 | 1.1 |
 | Postnatal check-up within 2 months of birth | - | 53.0 | 91.3 |
 | Institutional delivery | 64 | 79 | 87.8 |
 | Caesarean-section rate | 7.64 | 15.8 | 25.0 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Diagnostic method | Cut-off value | Sensitivity | Specificity | Accuracy | Reliability | P valuea |
 | --- | --- | --- | --- | --- | --- | --- |

[Assistant]
| LFpen | 8 | 92% | 90% | 95% | 0.95 | <0.001 |
 | Digital bitewing radiography | Radiolucency in enamel | 55% | 93% | 81% | 0.81 |  | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> | Over-sampling | <COLSPAN=2> SVM | <COLSPAN=2> MyC | <COLSPAN=2> RIPPER | <COLSPAN=2> C4.5 | Imbalance |
 | (%) | Sens. | Spec. | Sens. | Spec. | Sens. | Spec. | Sens. | Spec. | ratio |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | 0 | 0.62 | 0.92 | 0.69 | 0.90 | 0.75 | 0.89 | 0.69 | 0.88 | 16 |
 | 100 | 0.66 | 0.86 | 0.78 | 0.80 | 0.81 | 0.76 | 0.74 | 0.75 | 8 |
 | 200 | 0.71 | 0.81 | 0.84 | 0.71 | 0.84 | 0.65 | 0.77 | 0.67 | 5 |
 | 300 | 0.74 | 0.77 | 0.89 | 0.59 | 0.88 | 0.65 | 0.80 | 0.65 | 4 |
 | 400 | 0.76 | 0.73 | 0.89 | 0.51 | 0.86 | 0.64 | 0.81 | 0.61 | 3 |
 | 500 | 0.77 | 0.69 | 0.89 | 0.48 | 0.84 | 0.64 | 0.82 | 0.60 | 3 |
 | 600 | 0.78 | 0.66 | 0.91 | 0.48 | 0.89 | 0.59 | 0.82 | 0.60 | 2 |
 | 700 | 0.82 | 0.60 | 0.92 | 0.43 | 0.89 | 0.54 | 0.82 | 0.60 | 2 |
 | 800 | 0.82 | 0.57 | 0.94 | 0.37 | 0.86 | 0.60 | 0.82 | 0.61 | 2 |
 | 900 | 0.83 | 0.55 | 0.93 | 0.36 | 0.89 | 0.53 | 0.83 | 0.61 | 2 |
 | 1000 | 0.84 | 0.54 | 0.95 | 0.36 | 0.88 | 0.54 | 0.83 | 0.61 | 1 | </md>


[User] <|image|>Transcribe the figure into Markdown format.

[Assistant]
<md> | Primer name | Sequence 5'–3' |
 | --- | --- |
 | mATF3 | F-GCTGCTGCCAAGTGTCGAAA R-TACATGCTCAACCTGCACCG |
 | hATF3 | F-AAGAACGAGAAGCAGCATTTGAT R-TTCTGAGCCCGGACAATACAC |
 | GAPDH | F-TTGCCATCAACGACCCCTTCAT R-AGACTCCACGACATACTCAGCA |
 | Acta1 | F-GTGAGATTGTGCGCGACATC R-GGCAACGGAAACGCTCATT |
 | Col1α | F-CTGGCGGTTCAGGTCCAAT R-TTCCAGGCAATCCACGAGC |
 | cTGF | F-AGACCTGTGGGATGGGCAT R-GCTTGGCGATTTTAGGTGTCC |
 | TGFβ | F-CCTGGCCCTGCTGAACTTG R-GACGTGGGTCATCACCGAT |
 | MLC2a | F-GGCACAACGTGGCTCTTCTAA R-TGCAGATGATCCCATCCCTGT |
 | MLC2v | F-ATCGACAAGAATGACCTAAGGGA R-ATTTTTCACGTTCACTCGTCCT |
 | IL-6 | F-TAGTCCTTCCTACCCCAATTTCC R-TTGGTCCTTAGCCACTCCTTC |
 | CD68 | F-TGTCTGATCTTGCTAGGACCG R-GAGAGTAACGGCCTTTTTGTGA |
 | F4/80 | F-CCCCAGTGTCCTTACAGAGTG R-GTGCCCAGAGTGGATGTCT |
 | BNP | F-GAGGTCACTCCTATCCTCTGG R-GCCATTTCCTCCGACTTTTCTC | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | <ROWSPAN=2> Variables | <COLSPAN=3> Univariate analysis | <COLSPAN=3> Multivariate analysis |
 | Hazard Ratio | 95% CI | P value | Hazard Ratio | 95% CI | P value |
 | --- | --- | --- | --- | --- | --- | --- |
 | Sex | 1.15 | 0.70–1.89 | 0.58 | 1.03 | 0.60–1.77 | 0.91 |
 | Age | 0.93 | 0.59–1.46 | 0.75 | 0.76 | 0.45–1.29 | 0.31 |
 | Tumor size | 0.94 | 0.47–1.90 | 0.87 | 0.77 | 0.35–1.71 | 0.52 |
 | Differentiation | 1.30 | 0.72–2.37 | 0.38 | 1.07 | 0.54–2.14 | 0.84 |
 | Tumor location | 1.09 | 0.68–1.75 | 0.71 | 1.10 | 0.54–2.14 | 0.84 |
 | Depth of invasion | 1.49 | 0.80–2.76 | 0.21 | 1.81 | 0.76–4.33 | 0.18 |
 | LN metastasis | 1.31 | 0.73–2.34 | 0.36 | 1.31 | 0.62–2.79 | 0.48 |
 | Distant metastasis | 0.83 | 0.26–2.63 | 0.75 | 0.66 | 0.97–4.45 | 0.67 |
 | TNM stage | 1.30 | 0.77–2.19 | 0.33 | 0.70 | 0.30–1.63 | 0.41 |
 | HER2 expression | 1.61 | 0.94–2.74 | 0.08 | 5.98 | 0.97–36.72 | 0.054 |
 | HER3 expression | 2.20 | 1.38–3.52 | 0.001 | 1.82 | 0.93–3.57 | 0.08 |
 | HER2-HER3 co-expression | 1.56 | 0.88–2.75 | 0.13 | 6.21 | 0.95–40.89 | 0.057 |
 | Akt expression | 1.79 | 1.04–3.08 | 0.04 | 1.64 | 0.87–3.12 |

[Assistant]
0.13 |
 | p-Akt expression | 1.42 | 0.87–2.27 | 0.15 | 0.88 | 0.46–1.68 | 0.69 |
 | mTOR expression | 1.33 | 0.84–2.11 | 0.22 | 1.14 | 0.64–2.03 | 0.67 |
 | p-mTOR expression | 1.88 | 1.19–2.99 | 0.01 | 1.47 | 0.75–2.87 | 0.26 | </md>


[User] <|image|>Transcribe the picture into Markdown format.

[Assistant]
<md> |  |  | Female | Female | Male | Male |
 | --- | --- | --- | --- | --- | --- |
 |  |  | Control | SSRI | Control | SSRI |
 | N |  | 15 | 14 | 8 | 10 |
 | Body Weight | (g) | 35.3 ± 1.6 | 29.6 ± 1.7 * | 39.7 ± 2.1 | 35.0 ± 1.0* |
 | <ROWSPAN=2> Brain | (mg) | 457 ± 4 | 458 ± 4 | 421 ± 12 | 406 ± 8 |
 | (mg/g) | 13.3 ± 0.6 | 16.1 ± 0.9 * | 10.9 ± 0.7 | 11.3 ± 0.4 |
 | <ROWSPAN=2> Liver | (mg) | 1251 ± 103 | 1241 ± 70 |  |  |
 | (mg/g) | 37 ± 3 | 42 ± 2 |  |  |
 | <ROWSPAN=2> White adipose | (mg) | 2688 ± 308 | 1761 ± 396 |  |  |
 | (mg/g) | 73 ± 6 | 53 ± 9 |  |  |
 | <ROWSPAN=2> Brown adipose | (mg) | 127 ± 12 | 109 ± 12 |  |  |
 | (mg/g) | 3.6 ± 0.3 | 3.6 ± 0.3 |  |  | </md>


[User] <|image|>Encode the table in Markdown syntax.

[Assistant]
<md> | Description | IPD Cases linked to patient records | Completed Follow-up (%) | Vaccination status known (%) | With >1 Risk factor (%) * |
 | --- | --- | --- | --- | --- |
 | Number of subjects | 396 | 368 | 348 | 61 |
 | Male (%) | 198 (50.0) | 181 (49.2) | 171 (49.1) | 28 (45.9) |
 | Aged 65 + years (%) | 165 (41.7) | 156 (42.4) | 145 (41.7) | 43 (70.5) |
 | % VHR§ | - | 29 (7.9) | 23 (6.6) | - | </md>


[User] <|image|>Convert the table to Markdown syntax.

[Assistant]
<md> | Participant | <COLSPAN=2> Inner speaking | <COLSPAN=2> Inner seeing | <COLSPAN=2> Bodily sensory awareness |
 |  | ReSQ | DES | ReSQ | DES | ReSQ | DES |
 | --- | --- | --- | --- | --- | --- | --- |
 | 1 | 40 | 17 | 14 | 19 | 38.5 | 39 |
 | 2 | 40.5 | 22 | 57.5 | 22 | 31.5 | 36 |
 | 3 | 69 | 53 | 11 | 25 | 78.5 | 33 |
 | 4 | 20 | 39 | 60 | 42 | 20 | 8 |
 | 5 | 95 | 14 | 85 | 67 | 42 | 11 |
 | Max discrepancy | <COLSPAN=2> 81.0 | <COLSPAN=2> 35.5 | <COLSPAN=2> 45.5 | </md>


[User]
<|image|>What are the following diagram content in markdown style: <md> |  | SSA (m2/g) | BJH Mesopore Area (m2/g) | BJH Average Pore Width (Å) |
 | --- | --- | --- | --- |
 | BG before | 120 | 10 | – |
 | BG after | 93 | 3 |

[Assistant]
– |
 | MBG before | 472 | 224 | 30 |
 | MBG after | 359 | 162 | 30 | </md>


[User] <|image|>Transform the diagram into Markdown format.

[Assistant]
<md> | Endpoint/Analysis | RR | 95% CI | p-value | p* |
 | --- | --- | --- | --- | --- |
 | Severe | 0.53 | (0.285, 0.977) | 0.042 | 0.22 |
 | Mild | 2.14 | (0.624, 7.310) | 0.227 | 0.11 |
 | Composite | 0.665 | (0.388, 1.138) | 0.137 | 0.063 |
 | Global (WLW) | 0.702 | (0.405, 1.219) | 0.209 |  | </md>


[User] <|image|>Encode the table in Markdown syntax.

[Assistant]
<md> |  | Mean ± SEM | Range | Normal Values |
 | --- | --- | --- | --- |
 | Age (yr) | 28.3 ± 0.9 | 19 – 35 | - |
 | BMI (kg/m2) | 29.6 ± 1.3 | 19.4 – 45.0 | 20 – 25 |
 | Waist Circumference (cm) | 93.7 ± 2.7 | 70.0 – 123.0 | < 88 |
 | Menstrual Cycle Length (d) | 91.3 ± 15.0 | 28 – 365 | 21 – 38 |
 | LH:FSH | 2.4 ± 0.3 | 0.6 – 7.6 | < 2 |
 | mFG Score | 9.3 ± 1.0 | 0 – 24 | <8 |
 | Testosterone (nmol/L) | 2.3 ± 0.2 | 1.0 – 5.0 | < 2.5 |
 | SHBG (nmol/L) | 45.9 ± 3.9 | 13.0 – 95.3 | 18 – 114 |
 | Free Androgen Index | 6.2 ± 0.7 | 1 – 19 | < 5 |
 | DHEA-S (μmol/L) | 4.8 ± 0.3 | 1.8 – 8.8 | 0.9 – 12.0 |
 | Fasting Glucose (mmol/L) | 4.8 ± 0.1 | 4.2 – 6.1 | < 6.1 |
 | Fasting Insulin (pmol/L) | 78.3 ± 10.4 | 21.0 – 205.0 | 14.0 – 100.0 |
 | HOMA-IR | 2.9 ± 0.4 | 0.7 – 8.1 | < 3 | </md>


[User]
<|image|>What are the following picture content in markdown style: <md> | <ROWSPAN=2> Treatment | <COLSPAN=4> Fluorescence intensity (arbitrary units) |
 | Outer periclinal cytoplasm | Anticlinal cytoplasm | Inner periclinal cytoplasm | Total |
 | --- | --- | --- | --- | --- |
 | 0 h Control | 43 ± 7 | 0 | 33

[Assistant]
± 6 | 76 ± 10 |
 | 15 h Control | 385 ± 17 | 25 ± 5 | 13 ± 4 | 424 ± 19 |
 | 15 h Latrunculin B (100 nM) | 184 ± 18 | 121 ± 13 | 180 ± 15 | 505 ± 27 |
 | 15 h Jasplakinolide (100 nM) | 184 ± 25 | 101 ± 10 | 176 ± 25 | 461 ± 37 |
 | 15 h Nifedipine (100 μM) | 165 ± 11 | 111 ± 7 | 142 ± 8 | 418 ± 15 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> |  | <COLSPAN=2> CKD stages | P value |
 |  | Stage 1 & 2e GFR > 60 | Stage 3,4 & 5e GFR < 60 |  |
 | --- | --- | --- | --- |
 | Number (%) | 231 (57%) | 174 (43%) |  |
 | Age (years) | 56 (10) | 67 (8) | < 0.001 |
 | Proportion of males | 60 (26) | 40 (23) | 0.28 |
 | Duration of diabetes (years) | 9 (4) | 11 (4) | 0.001 |
 | Proportion Smokers | 36 (16) | 13 (7) | 0.009 |
 | BMI (kg/m2) | 24.7 (3.5) | 22.3 (3.4) | < 0.001 |
 | WHR | 0.88 (0.06) | 0.86 (0.07) | 0.04 |
 | SBP (mmHg) | 132 (17) | 136 (20) | 0.03 |

[Assistant]
| DBP (mmHg) | 76 (10) | 76 (10) | 0.96 |
 | Proportion of poor glycaemic control (HbA1c > 7.5%) | 86 (47) | 58 (48%) | 0.46 | </md>


[User] <|image|>Transcribe the table into Markdown format.

[Assistant]
<md> | Category | Drug selection | Dosage form | Dose | Frequency | Final result |
 |  | n (%) | n (%) | n (%) | n (%) | n (%) |
 | --- | --- | --- | --- | --- | --- |
 | A | 195 (43.4) | 171 (87.7) | 102 (59.6) | 99 (97.1) | 99 (22.1) |
 | IA | 254 (56.6) | 24 (12.3)a | (see below) | 3 (2.9) | 350 (78.0) |
 | OPD | - | - | 1 (0.6) | - | - |
 | UPD | - | - | 68 (39.8) | - | - |
 | NAI | 95 | 95 | 95 | 95 | 95 |
 | Total assessable | 449 | 195 | 171 | 102 | 449 |
 | Total | 544 | 290 | 266 | 197 | 544 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | <ROWSPAN=2> States | <COLSPAN=2> n = 1 | <COLSPAN=2> n = 2 | Experiment |
 | eV (nm) | f | eV (nm) | f | nm |
 | --- | --- | --- |

[Assistant]
--- | --- | --- |
 | S1 | 2.48(500.84) | 1.3006 | 2.40(515.68) | 2.8379 | 540 |
 | S2 | 3.51(353.23) | 0.0299 | 2.52(491.41) | 0.0625 | – |
 | S3 | 3.78(328.04) | 1.3606 | 3.40(364.33) | 0.1901 | 384 |
 | S4 | 4.09(302.68) | 0.0862 | 3.49(355.25) | 0.0006 | – |
 | S5 | 4.31(287.55) | 0.0023 | 3.67(337.96) | 1.7567 | – | </md>


[User] <|image|>Convert the picture into Markdown format.

[Assistant]
<md> |  | Current sample size | Target sample size |
 | --- | --- | --- |
 | Homologous IVF | 378 | 300 |
 | Sperm donation | 170 | 200 |
 | Embryo donation | 31 | 50 |
 | Egg donation | 146 | 200 |
 | Gestational Surrogacy | 16 | 30 | </md>


[User] <|image|>Convert the figure into Markdown language.

[Assistant]
<md> |  | NRLM NASDA/OCTS | NIST SXR | UA UAXR | NASA/GSFC 746/ISIC |
 | --- | --- | --- | --- | --- |
 | Quantity | 6 | 1 | 1 | 1 |
 | Type (quantity) | Filter (6) | Filter (6) | Filter (7) | Grating (1) |
 | Photodiode (quantity) | Silicon (6) | Silicon (6) | Silicon (3, trap (configuration) | Silicon (1) |
 | Target diameter (mm) | 4 | 45 | 76 | 384 |
 | Measurement distance (mm) | 500 | 900 | 900 | 535 |
 | Calibration method | Copper fixed-point blackbody | Radiance standard(sphere) | Irradiance standard lamp(F330) | Irradiance standard lamp(F315) |
 | <ROWSPAN=3> Saturation radiancea(W m−2 sr−1 μm−1) | 5.5 × 106 (443 nm) | 67 (442 nm) | ≈ 4700 (442 nm) |  |
 | 3.9 × 106 (490 nm) | 408 (487 nm) | ≈ 4600 (487 nm) |  |
 | 2.7 × 106 (670 nm) | 385 (662 nm) | ≈ 3200 (667 nm) |  | </md>


[User] <|image|>Convert the illustration into Markdown language.

[Assistant]
<md> | Variable | Mean | SD |
 | --- | --- | --- |
 | WTP (The highest bid which a person was willing to pay) (RMB/year) | 329.94 | 219.34 |
 | Annual per capita income (RMB) |  |  |
 | Lowest 25% | 3472.62 | 1519.34 |
 | Middle 25% | 7347.68 | 1009.81 |
 | Higher 25% | 12,874.09 | 2614.97 |
 | Highest 25% | 36,232.52 | 21,732.23 |
 | Variable | N | % |
 | Province |  |  |
 | Qinghai | 901 | 51.69 |
 | Zhejiang | 842 | 48.31 |
 | <COLSPAN=3> Sex |
 | Male | 1075 | 61.68 |
 | Female | 668 | 38.32 |
 | <COLSPAN=3> Age (year) |
 | ≤35 | 370 | 21.23 |
 | 35–65 | 972 | 55.77 |
 | ≥65 | 401 | 23.01 |
 | <COLSPAN=3> Marital status |
 | Married | 1292 | 74.13 |
 | Single, divorced, or widowed | 451 | 25.87 |
 | <COLSPAN=3> Education status |
 | Primary education or below | 538 | 30.87 |
 | Secondary education | 848 | 48.65 |
 | Tertiary education | 357 | 20.48 |
 | <COLSPAN=3> The type of public health insurance |
 | UEBMI | 508 | 29.15 |
 | URBMI/NCMS | 387 | 22.20 |
 | Not covered or did not know the type | 848 | 48.65 |
 | <COLSPAN=3> Having chronic conditions |
 | Yes | 621 | 35.63 |
 | No | 1122 | 64.37 | </md>


[User]
<|image|>Continue parse the picture with markdown style: <md> | Scale | Mean | SD | Range |
 | --- | --- | --- | --- |
 | ODI | 31.4 | 15.4 | 2–70 |
 | <COLSPAN=4> VAS

[Assistant]
|
 | Low back | 5.0 | 2.3 | 0–10 |
 | Legs | 3.7 | 2.4 | 0–10 |
 | <COLSPAN=4> SF-36 |
 | PHS | 193 | 74 | 32–359 |
 | MHS | 234 | 95 | 9–400 |
 | PCS | 31.9 | 9.9 | 4.1–55.0 |
 | MCS | 45.9 | 13.6 | 8.1–70.6 | </md>


[User] <|image|>Transcribe the figure into Markdown format.

[Assistant]
<md> | Exon | Forward 5′- 3′ | Reverse 5′- 3′ | Tm (°C) |
 | --- | --- | --- | --- |
 | 1 | M13F GTGAACCCTCAGCCAATCAG | M13R TGACGACGGGAGAGGAAG | 63 |
 | 2 | M13F TGTTGGTTTCGGTGAGCAG | M13R GGTGT3GGGAGTGCAATTTCT | 61 |
 | 3 | M13F CGCTCTTTGGAGAAGGAATG | M13R AACGGTACCAAGGCTGAGAA | 58 |
 | 4 | M13F GCTGTCTGGCTAGGTTGGAC | M13R TTTTCCCTTTCTCTCCTTGG | 58 |
 | 5 | M13F GAAAGGGAAAAGACCCAGTG | M13R GGATCCAGCATGGGTTGAC | 58 |
 | 6 | M13F GCCCCTTCTCCCATGTTT | M13R CTTTGGGCTTGGACAACACT | 56 |
 | 7 | M13F GGGCAGAATTGGATTAAGCA | M13R TGTCCACGGGATTGAGCTA | 57 |
 | 8 | M13F CTGGGTAGGCCAAAGGT | M13R CCATGAGCAGTGGTGACACTT | 57 |
 | 9 | M13F AATCCTTTAGCCCCCTGAGA | M13R AGGGGACAAGGGTATGAACA | 61 |
 | 10 | M13F CCAAAAGCAACAGTTAAGGA | M13R CAAATGACAAAATGCCATGA | 56 |
 | 11 | M13F AGCGCTTAAGCCGTTTTCA | M13R GAGGGGCAAGGAACTGAACT | 60 |
 | 12 | M13F AAGGCAATGGGGATTCATTA | M13R ATTGAAAGGTGGGGATCTGG | 59 |
 | 13 | M13F CAATTTTATTCTGGAATGAGCTTTT | M13R CAGGAAATAAACCTCCTCCATTT | 55 |
 | 14 | M13F GCTGCTTCTGGCCTTCTTA | M13R GCTGTTTCAAATGCCTACCTCT | 55 |
 | 15 | M13F TGAACATAGCCCTGTGTGTATG | M13R TTTTGACACAACTCCTCCTG | 58 |
 | 16 | M13F AGACTTCTTGCCCCAGATGA | M13R AACCACCAGCAACGTGATTT | 63 | </md>


[User] <|image|>Interpret the image as Markdown format.

[Assistant]
<md> | FC | p-value | Symbol | Entrez gene name |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Up-regulation |
 | 48.16 | 6.4E-05 | PLIN1 | perilipin 1 |
 | 32.22 | 9.2E-07 | LMOD2 | leiomodin 2 (cardiac) |
 | 30.27 | 7.9E-04 | CA3 | carbonic anhydrase III |
 | 26.72 | 1.7E-07 | MUSTN1 | musculoskeletal, embryonic nuclear protein 1 |
 | 20.96 | 1.2E-05 | TNNT2 | troponin T type 2 (cardiac) |
 | 19.97 | 4.8E-06 | HSPB7 | heat shock 27 kDa protein family, member 7 (cardiovascular) |
 | 18.12 | 1.0E-06 | NOXO1 | NADPH oxidase organizer 1 |
 | 13.83 | 8.1E-05 | PLN | phospholamban |
 | 12.99 | 2.8E-05 | PCSK1 | proprotein convertase subtilisin/kexin type 1 |
 | 12.55 | 9.2E-04 | MYBPC1 | myosin binding protein C, slow type |
 | <COLSPAN=4> Down-regulation |
 | −13.36 | 9.6E-07 | IL23R | interleukin 23 receptor |
 | −11.39 | 4.2E-05 | GPM6A | glycoprotein M6A |
 | −8.81 | 1.5E-02 | KL | klotho |
 | −7.72 | 7.8E-05 | AGMAT | agmatine ureohydrolase (agmatinase) |
 | −7.72 | 1.1E-04 | DKK2 | dickkopf WNT signaling pathway inhibitor 2 |
 | −7.21 | 1.4E-03 | GABRD | gamma-aminobutyric acid (GABA) A receptor, delta |
 | −6.54 | 4.5E-03 | FGB | fibrinogen beta chain |
 | −6.49 | 1.1E-06 | PPDPF | pancreatic progenitor cell differentiation and proliferation factor |
 | −6.02 | 4.5E-06 | ACE | angiotensin I converting enzyme |
 | −5.93 | 3.6E-05 | CD9 | CD9 molecule | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | Effect | df | F value | P value |
 | ---

[Assistant]
| --- | --- | --- |
 | Focal/Competitor type (FC) | 5, 291 | 79.39 | <0.0001 |
 | Density | 1, 291 | 216.34 | <0.0001 |
 | Interaction: FC*Density | 5, 291 | 0.83 | 0.5321 |
 | Contrast: FC LH vs. LL | 1, 291 | 6.30 | 0.0126 |
 | Contrast: FC HL vs. HH | 1, 291 | 10.94 | 0.0011 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | <COLSPAN=2> Characteristics | Count | Median | Interquartile range |
 | --- | --- | --- | --- | --- |
 | Sex | Female | 22 |  |  |
 |  | Male | 56 |  |  |
 | <COLSPAN=2> Age (years) |  | 69 | 14 |
 | <COLSPAN=2> BMI |  | 25.5 | 5.35 |
 | <COLSPAN=2> Ejection fraction (%) |  | 50 | 10 |
 | Diabetic status | No diabetes | 57 |  |  |
 |  | Diabetes type 1 | 2 |  |  |
 |  | Diabetes type 2 | 19 |  |  |
 | Surgical procedure | CABG | 33 |  |  |
 |  |

[Assistant]
AVR | 24 |  |  |
 |  | AVR + CABG | 7 |  |  |
 |  | MVR | 2 |  |  |
 |  | MVR + CABG | 1 |  |  |
 |  | Aortic graft | 4 |  |  |
 |  | AVR + aortic graft | 5 |  |  |
 |  | Other | 2 |  |  |
 | <COLSPAN=2> Time of extracorporeal circulation (min) |  | 78 | 53 |
 | <COLSPAN=2> Time of aortic cross-clamping (min) |  | 56 | 47 |
 | Vasoactive drugs | None | 4 |  |  |
 |  | NA | 9 |  |  |
 |  | Nitro | 30 |  |  |
 |  | NA + Nitro | 29 |  |  |
 |  | NA + Nitro + A | 1 |  |  |
 |  | NA + Nitro + Milrinone | 1 |  |  |
 |  | NA + Nitro + Levosimendan | 1 |  |  |
 | <ROWSPAN=3>  | NA + Milrinone | 1 |  |  |
 | NA + Milrinone + A | 1 |  |  |
 | NA + Milrinone + Levosimendan | 1 |  |  |
 | Transfusions | Red blood cells | 44 | 2 | 4 |
 |  | Plasma | 16 | 0 | 1 | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | Process | Functional Relevance of Exopolysaccharides to Biofilms |
 | --- | --- |
 | Adhesion | Exopolysaccharides makes provision for the initial steps in the colonization of surfaces (abiotic and biotic) and long-term attachment of biofilms. |
 | Bacterial cell aggregation | The bridging between cells is enabled by exopolysaccharides, thus temporarily immobilizing bacterial population thus, the subsequent development of high cell densities and cell–cell recognition. |
 | Water retention | Hydrophilic exopolysaccharides have high water retention ability thus maintaining a hydrated microenvironment around biofilm and this leading to the survival of desiccation in water-deficient environments. |
 | Cohesion of biofilms | Neutral and charged exopolysaccharides forms a hydrated polymer network (the biofilm matrix), mediating the mechanical stability of biofilms (often in conjunction with multivalent cations), determining biofilm architecture, as well as allowing cell-cell communication. |
 | Nutrient source | Exopolysaccharides serves as source of carbon, nitrogen and phosphorus containing compounds for utilization by the biofilm community. |
 | Protective barrier | Exopolysaccharides confers resistance to non specific and specific host defences during infection, confers tolerance to various antimicrobial agents, protects cyanobacterial nitrogenase from the harmful effects of oxygen and offers protection against some phagocytic protozoa. |
 | Sorption of organic Compounds and inorganic ions | Charged and hydrophobic exopolysaccharides mediates the accumulation of nutrients from the environment, sorption of xenobiotics and recalcitrant materials. They promote polysaccharide gel formation resulting in ion exchange, mineral formation and the accumulation of toxic metal ions (thus collectively contributing to environmental detoxification). |
 | Binding of enzymes | Non glycolytic extracellular enzyme interaction with exopolysaccharides leads to retention stabilization and accumulation. |
 | Export of cell components | Lipopolysaccharides (isoprenoid glycosyl carrier lipids), which lipo-glyco conjugate, mediates the releases cellular material as a result of metabolic turnover. |
 | Sink for excess energy | Exopolysaccharides stores excess carbon under unbalanced carbon to nitrogen ratios. | </md>


[User] <|image|>Transform the table into Markdown format.

[Assistant]
<md> |  | α valuesof SF | α valuesof foci 24 h | RBE(SF 0.1) | RBE(foci 24 h) |
 | --- | --- | --- | --- | --- |
 | 220 kV X-rays LDR, reference | 0.12 | 0.84 | 1.00 | 1.00 |
 | 220 kV X-rays HDR | 0.24 | 1.87 | 0.58 | 2.22 |
 | <En > = 5.8 MeV neutrons LDR | 0.43 | 4.43 | 2.06 | 5.25 |
 | <En > = 5.8 MeV neutrons HDR | 0.65 | 3.86 | 1.99 | 4.57 |
 | 1.2 MeV monoenergetic neutrons | 1.91 | 3.36 | 3.75 | 3.98 |
 | 0.56 MeV monoenergetic neutrons | 2.55 | 6.71 | 4.97 | 7.95 |
 | mixed gamma – secondary neutron (<En > = 70.5 MeV) field | 1.03 | 3.77 | 2.09 | 4.47 | </md>


[User] <|image|>Render the image in Markdown format.

[Assistant]
<md> | Conc. | % | <COLSPAN=2> Inhibitions | ABTS | radicals |
 | mg/mL | Unripe | Ripe | Vit. C | β- carotene |  |
 | --- | --- | --- | --- | --- | --- |
 | 0.05 | 45 | 47.25 | 34 | 53 |  |
 | 0.10 | 55 | 60.2 | 44 | 61 |  |
 | 0.20 | 61 | 88 | 50 | 83 |  |
 | 0.40 | 80 | 92 | 55.48 | 92 |  |
 | 0.50 | 90.23 | 95 | 81.45 | 96 |  | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | Percentages nominated for each method | 1 | 2 |
 | --- | --- | --- |
 | Interviews with your GP supervisor | 58 | 21 |
 | A buddy system | 57 | 26 |
 | Seeing your own GP | 53 | 9 |
 | Informal means (eg., staff noticing changes in demeanour)

[Assistant]
| 46 | 13 |
 | Interviews with a VMA representative (eg., psychologist) | 35 | 10 |
 | Stress screening on the annual GP registrar satisfaction survey | 34 | 7 |
 | Psychological paper and pencil test | 26 | 6 |
 | Chat room forum facilitating discussion about registrar stress | 23 | 3 | </md>


[User] <|image|>Render the figure in Markdown format.

[Assistant]
<md> | Expression status | Intracellular expression localization | Proteins |
 | --- | --- | --- |
 | <ROWSPAN=3> Equal expression in both tumour types | Nuclear | VEGFA, TYMP, KDR, KDRp34, FIH, EPHB4, PHD1, SOD1, FGF, P53, SP1, STAT3, MEF2D, JMY, GST, CHGA |
 | Cytoplasm | HIF1, HIF2, VEGFA, TYMP, KDR, KDRp34, FIH, PHD1, SOD1, CXCR4, EPHB4, BCL2, EGF, EGFR, FGF, BNIP3, PI3, SP1, LON, MEF2D, GST, CHGA, SYP |
 | Membrane | CA9, MEF2D |
 | <ROWSPAN=3> Higher expression in angiogenic tumours than in non-angiogenic tumours in at least one subcellular location | Nuclear | HIF1, PHD2, PHD3, CXCR4, BNIP3, PI3, EGF, FOS |
 | Cytoplasm | PHD2, TSP (stroma), DLL4 (endothelium), FOS, STAT3 |
 | Membrane | None |
 | <ROWSPAN=3> Higher expression in non-angiogenic tumours than in angiogenic tumours in at least one subcellular location | Nuclear | EPHB2, EPHB3,TRAP1 |
 | Cytoplasm | CA9, PHD3, EPHB2, EPHB3, NCAM, P53, TRAP1, JMY |
 | Membrane | EPHB3, GST | </md>


[User] <|image|>Convert the picture into Markdown format.

[Assistant]
<md> | Sample | Malathion Added (nM) | Malathion Found (nM) | Recovery (%) | RSD (%, n = 3) |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=2> Tomato | 0.893 | 1.02 | 114.2 | 7.9 |
 | 11.01 | 10.1 | 91.7 | 10.5 |
 | <ROWSPAN=2> Apple | 0.893 | 0.814 | 91.1 | 2.3 |
 | 1.488 | 1.570 | 105.5 | 10.4 | </md>


[User]
<|image|>Parse the figure content behind with markdown code: <md> | Verbal Memory Process | <COLSPAN=2> Verbal Delayed Index (CMS) | <COLSPAN=2> Vocabulary (WISC-IV) | <COLSPAN=2> Similarities (WISC-IV) | <COLSPAN=2> Comprehension (WISC-IV) |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | CMS Score | r | n | r | n | r | n | r | n |
 | EncodingImmediate Memory | 0.77 ** | 232 | 0.51 ** | 193 | 0.49 ** | 193 | 0.51 ** | 193 |
 | RetentionRetention | 0.04 | 180 | −0.03 | 150 | 0.10 | 150 | −0.01 | 150 |

[Assistant] | RetrievalDelayed Memory Contrast | 0.44 ** | 212 | 0.06 | 176 | 0.15 * | 176 | 0.08 | 176 | </md>


[User] <|image|>Transform the illustration into Markdown format.

[Assistant]
<md> | Species | sRNA | Subunit | D target | D' target |
 | --- | --- | --- | --- | --- |
 | Iho | sR114 | 23S | C1961 | C2265 |
 | Iho | sR114 | 23S | C2275 | D1937 |
 | Iho | sR472 | 23S | C897 | G1017 |
 | Iho | sR206 | 16S | G*36 and 505 | G482 |
 | Iho | sR103 | 16S | C1045 | U1136 |
 | Pca | sR53 | 16S | A509 | C34 and 530 |
 | Pca | sR56 | 16S | U894 | G1358 and G925 |
 | Pca | sR2 | 23S | G747 | C884 and 769 |
 | Mka | sR87 | 23S | A1241 | G1385 |
 | Neq | sR15 | 16S | G1217 | G930 |
 | Neq | sR17 | 16S | U1370 | A915 |
 | Tte | sR51 | 23S | C1947 | G2249 and 1980 |
 | Tte | sR50 | 23S | U2883 and 2783 | U2753 |
 | Tte | sR46 | 16S | U547 and 984 | G924 |
 | Tte | sR15 | 16S | A509 | C35 and 530 | </md>


[User]
<|image|>Continue parse the illustration with markdown style: <md> | Recipient Mice* | Number of mice | Number with tumor | p‡ |
 | --- | --- | --- | --- |
 | Rag2-/- | 15 | 15 | _ |
 |

[Assistant]
C57Bl/6 | 15 | 1 | 0.0001 |
 | UV-irradiated C57Bl/6† | 15 | 2 | 0.0001 | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | AP | BZD | AD | MS | AH |
 | --- | --- | --- | --- | --- |
 | 59.3 | 40.7 | 0 | 0 | 0 |
 | 40.7 | 54.6 | 1.9 | 1.9 | 0.9 |
 | 0 | 1.9 | 31.8 | 37.4 | 29.0 |
 | 0 | 1.9 | 38.3 | 34.6 |

[Assistant]
25.2 |
 | 0 | 0.9 | 28.0 | 26.2 | 44.9 | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> | <COLSPAN=2> polymorphism | natural rateb | <COLSPAN=2> EMS | <COLSPAN=2> Az-MNU |
 | type | changea |  | obc | exd | ob | ex |
 | --- | --- | --- | --- | --- | --- | --- |
 | transitions | GC->AT | 0.32 | 19 | 8.53 | 20 | 9.48 |
 |  | AT->GC | 0.35 | 3 | 9.48 | 6 | 10.53 |
 | transversions | GC->TA | 0.09

[Assistant]
| 1 | 2.33 | 0 | 2.59 |
 |  | GC->CG | 0.07 | 0 | 1.84 | 0 | 2.05 |
 |  | AT->TA | 0.09 | 4 | 2.30 | 2 | 2.55 |
 |  | AT->CG | 0.09 | 0 | 2.52 | 2 | 2.80 |
 | <COLSPAN=7> Statistical analysise |
 | transitions | GC->AT | 0.32 | 19 | 8.53 | 20 | 9.48 |
 |  | AT->GC |  |  |  |  |  |
 | transversions | GC->TA |  |  |  |  |  |
 |  | GC->CG | 0.68 | 8 | 18.46 | 10 | 20.52 |
 |  | AT->TA |  |  |  |  |  |
 |  | AT->CG |  |  |  |  |  |
 | <COLSPAN=3> Probability | <COLSPAN=2> 0.0067 | <COLSPAN=2> 0.0042 | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | Year | Women who went through OSI (n = 29) | Women from national controls (n = 77,514) | Odds ratio (95% CI) | p value |
 | --- | --- | --- | --- | --- |
 | 2011 | 2/7 (29%) | 224/18,953 (1%) | 33.4 (3.2–205.3) | 0.003 |
 | 2012 | 2/5 (40%) | 187/19,072 (1%) | 67.3 (5.6–590) | 0.001 |
 | 2013 | 2/7 (29%) | 158/19,662

[Assistant]
(1%) | 49.4 (4.7–303.8) | 0.001 |
 | 2014 | 3/10 (30%) | 231/19,827 (1%) | 36.6 (6–160.3) | < 0.001 |
 | Overall | 9/29 (31%) | 800/77,514 (1%) | 43.2 (17.2–99.6) | < 0.001 | </md>


[User]
<|image|>Continue parse the figure with markdown style: <md> | Method | Sensitivity (%) | Specificity (%) | *PPV(%) | *NPV(%) | *Prevalence(%) | Reference gold standard | Author and date of publication |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | *KK | 51.1-84.1 | 100 | 100 | 93.2-96.5 | 13.0-18.4 | two repeated KK results (6 slides) | Lin et al. 2008 [13] |
 |  | 59.6-70.0 | 100 | 100 | 93.3-97.9 | 6.6-18.6 | two repeated KK results (6 slides) | Zhou et al. 2007 [14] |
 |  | 72.2-100.0 | 100 | 100 | 96.3-100.0 | 6.2-12.0 | combined results of KK(3 slides) and MHT | Xu et al. 2007 [15] |
 |  | 58.3 | 100 | 100 | 83.5 | 32.1 | MHT | He et al. 2007 [16] |
 |  | 67.6 | 100 | 100 | 58.9 | 68.3 | seven repeated KK examinations (14 slides) | Yu et al. 2007 [17] |
 |  | 69.9 | 100 | 100 | 95.63 | 13.2 | combined results of KK(3 slides) and MHT | Zhu et al. 2005 [18] |
 |  | 50.0 | 100 | 100 | 98.02 | 3.9 | combined results of KK(3 slides) and MHT | Song et al. 2003 [19] |
 |  | 40-68 | 100 | 100 | 52.5-80.5 | 36.0-68.3 | seven accumulated KK results(14 slides) | Yu et al. 1998 [20] |
 | *MHT | 24.0-95.0 | 100 | 100 | 95.2-99.6 | 6.2-12.0 | combined results of KK (3 slides) and MHT | Xu et al.2007 [15] |
 |  | 79.2 | 100 | 100 | 94.0 | 23.6 | KK(3 slides) | He et al. 2007 [16] |
 |  | 32.8 | 100 | 100 | 40.9 | 68.3 | seven accumulated KK

[Assistant]
results (14 slides) | Yu et al. 2007 [17] |
 |  | 89.8 | 100 | 100 | 98.5 | 13.2 | combined results of KK(3 slides) and MHT | Zhu et al.2005 [18] |
 |  | 94.4 | 100 | 100 | 99.8 | 3.9 | combined results of KK(3 slides) and MHT | Song et al. 2003 [19] | </md>


[User]
<|image|>Parse the following content of the image in markdown code: <md> | Characteristics | Coefficient | SE (coeff.) | Sig. | Partial log likelihood |
 | --- | --- | --- | --- | --- |
 | Life expectancy: maximal increase | 0.735 | 0.152 | *** | −717.7 |
 | Long term side effects improbable (<20%) | 0.408 | 0.147 | ** | −709.5 |
 | Flexibility of dosing: max. 3 tablets/day | 0.454 | 0.151 | ** | −710.1 |
 | Physical quality of life: diarrhoea, nausea less frequent | 1.611 | 0.152 | *** | −769.4 |
 | Emotional quality

[Assistant]
of life: disease not obvious for others | 2.984 | 0.153 | *** | −981.7 |
 | Social quality of life: participation in social life possible | 1.140 | 0.153 | *** | −735.4 |
 | Model constant | −3.726 | 0.214 | *** |  | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> |  | PG (n = 21)a | AD (n = 21)a | HC (n = 21)a | Test statistic | Post-hoc effects of group |
 | --- | --- | --- | --- | --- | --- |
 | Cambridge Gamble Task |  |  |  |  |  |
 | Total points obtained | 1772 ± 1205 | 1605 ± 805 | 1551 ± 592 | F(2,60) = 0.34, NS | – |
 | Bankruptciesb | 5 (24%) | 4 (19%) | 0 (0%) | χ2(1) = 5.25, P = 0.022 | – |
 | % Rational decisions | 90 ± 19 | 94 ± 9 | 96 ± 9 | F(2,60) = 1.15, NS | – |
 | Percentage wager | 59 ± 17 | 56 ± 11 | 48 ± 13 | F(2,56) = 3.31, P = 0.045 | PG>HC |
 | Decision latency (ms) | 2064 ± 739 | 2742 ± 1136 | 1970 ± 753 | F(2,56) = 5.74, P = 0.005 | AD>[PG=HC] |
 | Information Sampling Task |  |  |  |  |  |
 | Errors | 5.0 ± 3.2 | 4.8 ± 2.5 | 3.2 ± 2.4 | F(2,60) = 2.41, P = 0.099 | PG>HC |
 | Boxes opened (/25) | 8.6 ± 3.6 | 9.8 ± 4.1 | 12.8 ± 4.6 | F(2,60) = 5.92, P = 0.005 | [PG=AD]<HC |
 | Spatial working memory |

[Assistant]
 |  |  |  |  |
 | Total errors | 23.3 ± 22.8 | 40.3 ± 30.0 | 22.8 ± 21.4 | F(2,57) = 3.20, P = 0.048 | AD>[PG=HC] |
 | Strategy | 32.0 ± 6.2 | 31.8 ± 8.5 | 29.5 ± 5.4 | F(2,57) = 0.73, NS | – |
 | Digit span |  |  |  |  |  |
 | Forwards score (/12) | 9.7 ± 1.8 | 8.3 ± 1.9 | 10.1 ± 1.8 | F(2,57) = 5.30, P = 0.008 | AD<[PG=HC] |
 | Backwards score (/12) | 8.6 ± 3.0 | 6.5 ± 2.2 | 7.8 ± 2.5 | F(2,57) = 3.51, P = 0.037 | AD<PG | </md>


[User]
<|image|>What are the following illustration content in markdown style: <md> | <COLSPAN=2> Group | Experimental | Control | Total | <ROWSPAN=2> P-value |
 | <COLSPAN=2> Demographic characteristics | Mean (±SD) | Mean (±SD) | Mean(±SD) |
 | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=2> Age | 34.87 (±7.8) | 36.06 (±8.03) | 33.46(±7.91) | 0.79 |
 | <COLSPAN=2>  | Frequency (%) | Frequency (%) | Frequency (%) |  |
 | Sex | Female | 27 (90) | 26 (83.8) | 53 (86.9) | 0.48 |
 | <ROWSPAN=2> Education | Bachelor’s degree | 26 (86.7) | 30 (96.8) | 56 (91.8) | <ROWSPAN=2> 0.15 |
 | Master’s degree | 4 (13.3%) | 1 (3.2%) | 5 (8.2) |
 | <ROWSPAN=2> Position | Nurse

[Assistant]
| 21 (70) | 27 (87.1) | 48 (78.68) | <ROWSPAN=2> 0.27 |
 | Supervisor | 9 (30) | 4 (12.9) | 13 (21.32) | </md>


[User]
<|image|>Parse the following content of the illustration in markdown code: <md> | Characteristic | Frequency |
 | --- | --- |
 | Mean age | 57 y (SD:±14y) |
 | <ROWSPAN=2> Sex | Fem: 141 (78.3%) |
 | Male: 39 (21.7%) |
 | <ROWSPAN=2> Origin | Urban: 124 (68.9%). |
 | Non-Urban: 56 (31.1%). |
 | Thyroid cancer family backgrounds | N (%) |
 | No | 119 (66.1%) |
 |

[Assistant]
Yes | 61 (33.9%) |
 | Accelerated Growth of the Thyroid Nodules |  |
 | No | 121 (67.2%) |
 | Yes | 59 (32.8%) |
 | Head Radiation |  |
 | No | 163 (90.6%) |
 | Yes | 17 (9.4%) |
 | Firm Nodule |  |
 | No | 94 (51.7%) |
 | Yes | 86 (47.8%) |
 | Adjacent structure Attachment |  |
 | No | 130 (72.2%) |
 | Yes | 50 (27.8%) |
 | Vocal Chord Paralysis |  |
 | No | 130 (72.2%) |
 | Yes | 50 (27.8%) |
 | ≥4 cm nodule |  |
 | No | 109 (60.6%) |
 | Yes | 71 (39.4%) | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | Title | Definition | Numerator | Denominator | Target |
 | --- | --- | --- | --- | --- |
 | <ROWSPAN=3> Retention in care at 12 months of ART | <ROWSPAN=3> Percentage of adults and children known to be alive and on ART 12 months after initiation | <ROWSPAN=3> Number of adults and children who are still alive and on ART 12 months after initiating treatment | <ROWSPAN=3> Total number of adults and children (excluding transfers out) who initiated ART and were expected to achieve 12-month outcomes within the reporting

[Assistant]
period | Desirable or excellent performance: >85% |
 | Fair performance: 75–85% |
 | Poor performance: <75% | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> | Cardiac characteristics | PBS | Cocaine |
 | --- | --- | --- |
 | Number of animals | 8

[Assistant]
| 8 |
 | Body weight (BW), gm | 340.70 ± 33.40 | 319.50 ± 11.80 |
 | Whole heart weight (wet WHW), gm | 1.51 ± 0.18 | 1.31 ± 0.18 |
 | WHW/BW (×104) | 44.76 ± 7.14 | 41.21 ± 5.80 | </md>


[User] <|image|>Interpret the picture as Markdown format.

[Assistant]
<md> | Baseline characteristics | Mean (SD), median (IQR) or number (%) | Correlation with frailty index at follow-up |
 | --- | --- | --- |
 | Age (years), mean (SD) | 70.0 (7.36) | 0.3012*** |
 | Female, no. (%) | 2982 (54.4) | 0.128*** |
 | <COLSPAN=3> Personality traits, mean (SD) |
 | Extraversion | 3.15 (0.55) | −0.249*** |
 | Agreeableness | 3.51 (0.48) | 0.015 |
 | Openness | 2.86 (0.56) | −0.165*** |
 | Neuroticism | 2.06 (0.58) | 0.161*** |
 | Conscientiousness | 3.27 (0.50) | −0.224*** |
 | Household wealth (£), median (IQR) | 241,102 (131,215–418,219) | −0.292*** |
 | Smoking status, no. (%) |  | 0.103*** |
 | Never | 1956 (36.8) |  |
 | Ex-smoker | 2822 (53.1) |  |
 | Current smoker | 536 (10.1) |  |
 | Physical activity, no. (%) |  | −0.415*** |
 | Sedentary | 279 (5.25) |  |
 | Low | 1294 (24.4) |  |
 | Medium | 2749 (51.7) |  |
 | High | 992 (18.7) |  |
 | Frailty index score, median (IQR) | 0.068 (0.022–0.136) | 0.830*** | </md>


[User] <|image|>Express the photo as Markdown code.

[Assistant]
<md> | <ROWSPAN=2>  | <COLSPAN=2> Crude |  | <COLSPAN=2> Adjusted |  |
 | HR | 95%-CI | p | HR | 95%-CI | p |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=7> Gender |
 | Men | 1.0 | ref |  | 1.0 | ref |  |
 | Women | 2.39 | 1.95–2.94 | 0.005 | 0.94 | 0.75–1.17 | 0.58 |
 | <COLSPAN=7> Age |
 | 15–39 | 1.0 | ref |  | 1.0 | ref |  |
 | 40–64 | 4.28 | 2.72–6.74 | < 0.005 | 3.67 | 2.32–5.81 | < 0.001 |
 | 65–101 | 31.1 | 20.3–47.8 | < 0.005 | 22.9 | 14.7–35.7 | < 0.001 |
 | <COLSPAN=7> Amputation |
 | No | 1.0 | ref |  | 1.0 | ref |  |
 | Yes | 2.6 | 1.60–4.23 | < 0.005 | 1.79 | 1.08–2.95 | 0.02 |
 | <COLSPAN=7> Length of stay |
 | Unit per extra day | 1.011 | 1.009–1.014 | < 0.005 | 1.01 | 1.009–1.017 | < 0.001 |
 | <COLSPAN=7> Mechanism of injury |
 | Fall from standing height (n = 66) | 1.0 | ref |  | 1.0 | ref |  |
 | Fall from height (n = 19) | 0.51 | 0.38–0.67 | < 0.005 | 0.59 | 0.44–0.78 | < 0.001 |
 | Unprotected road users (n = 8) | 0.21 | 0.15–0.28 | < 0.005 | 0.34 | 0.25–0.48 | < 0.001 |
 | Car crash (n = 2) | 0.21 | 0.13–0.36 | < 0.005 | 0.36 | 0.21–0.62 | < 0.001 |
 | Other vehicles/objects (n = 4) | 0.17 | 0.10–0.29 | < 0.005 | 0.30 | 0.18–0.51 | < 0.001 |
 | Self-destructive injury (n = 3) | 0.40 | 0.18–0.91 | 0.029 | 1.20 | 0.53–2.75 | 0.66 |
 | Else (n = 10) | 0.43 | 0.29–0.63 | < 0.005 | 0.48 | 0.32–0.72 | < 0.001 | </md>


[User]
<|image|>What are the following figure content in markdown style: <md> |  |  | IRR | <COLSPAN=2> 95% CI | P-value |  |
 | --- | --- | --- | --- | --- | --- | --- |
 | <COLSPAN=2> NDVI 2 weeks before catch | 0.000 | 0.000 | 0.135 | 1.22e-02 | * |
 | <COLSPAN=2> Cumulated precipitation 16 days preceding the catch (per additional mm) | 1.006 | 1.001 | 1.011 | 2.89e-02 | * |
 | <ROWSPAN=2> Aquatic grassland | Absence | 1 |  |

[Assistant]
 |  |  |
 | Presence | 4.713 | 2.179 | 10.194 | 8.20e-05 | *** |
 | <ROWSPAN=3> Vector control intervention | TLLIN | 1 |  |  |  |  |
 | ULLIN | 0.605 | 0.334 | 1.097 | 9.80e-02 | . |
 | ULLIN + CTPS | 0.168 | 0.056 | 0.504 | 1.40e-03 | ** |
 |  | TLLIN + IRS | 0.447 | 0.168 | 1.189 | 1.07e-01 |  | </md>


[User] <|image|>Convert the illustration into Markdown format.

[Assistant]
<md> | <ROWSPAN=2> Disease group | <ROWSPAN=2> No. of patients | <ROWSPAN=2> Age (years); mean ± SE | <COLSPAN=2> Gender |
 | Male | Female |
 | --- | --- | --- | --- | --- |
 | Dry AMD | 5 | 80 ± 7 | 1 | 4 |
 | nAMD | 11 | 80 ± 5 | 4 | 7 |
 | PDR | 9 | 59 ± 2 | 4 | 5 |
 | ERM | 11 | 71 ± 4 | 5 | 6 | </md>


[User] <|image|>Encode the photo in Markdown syntax.

[Assistant]
<md> |  | <COLSPAN=4> % Packout by Fruit Grade |
 |  | Premium | 2nd | 3rd | Total |
 | --- | --- | --- | --- | --- |
 | No Agsil Drench a | 50.3 | 21.1 | 26.2 | 97.6 |
 | Agsil Drench b | 51.3 | 36.5 | 10.8 | 98.6 | </md>


[User] <|image|>Convert the photo to Markdown syntax.

[Assistant]
<md> |  | Closed‐loop period (n = 40) | Control period (n = 40) | p |
 | --- | --- | --- | --- |
 | Mean ± s.d. glucose, mmol/l | 8.6 ± 1.2 | 9.1 ± 1.4 | 0.016 |
 | <COLSPAN=4> Mean ± s.d. proportion of time spent at glucose level, % |
 | 3.9–10.0 mmol/l | 63.6 ± 9.9 | 58.8 ± 10.5 | 0.001 |
 | >10.0 mmol/l | 29.5 ± 10.5 | 36.5 ± 13.3 | <0.001 |
 | Median (IQR) proportion of time spent at glucose level <3.9 mmol/l, % | 1.8 (0.91, 3.2) | 2.7 (1.3, 5.7) | 0.015 |
 | Median (IQR) AUCday < 3.5 mmol/l, mmol/l × min | 5.2 (2.0, 12.1) | 6.9 (2.4, 29.5) | 0.078 | </md>


[User] <|image|>Encode the diagram in Markdown syntax.

[Assistant]
<md> |  | <COLSPAN=2> Factors levels in actual values |  |  |  |
 | Formula | Pluronic to drug ratio | P123 percentage (%) | EE% + SD (%)a | PS + SD (nm)a | PDI + SDa |
 | --- | --- | --- | --- | --- | --- |
 | M1 | 10 | 10 | 7.27 ± 0.47 | 58.73 ± 1.56 | 0.23 ± 0.01 |
 | M2 | 50 | 10 | 98.72 ± 0.72 | 26.34 ± 0.09 | 0.14 ± 0.01 |
 | M3 | 10 | 90 | 79.22 ± 1.00 | 26.83 ± 0.96 | 0.29 ± 0.03 |
 | M4 | 50 | 90 | 99.55 ± 0.18 | 20.03 ± 0.21 | 0.08 ± 0.02 |
 | M5 | 10 | 50 | 64.28 ± 0.98 | 26.07 ± 1.07 | 0.32 ± 0.04 |
 | M6 | 50 | 50 | 96.69 ± 0.77 | 23.46 ± 0.29 | 0.14 ± 0.02 |
 | M7 | 30 | 10 | 97.35 ± 0.25 | 29.93 ± 0.76 | 0.18 ± 0.01 |
 | M8 | 30 | 90 | 98.15 ± 0.89 | 20.65 ± 0.20 | 0.15 ± 0.01 |
 | M9 | 30 | 50 | 97.75 ± 0.16 | 23.13 ± 0.16 | 0.15 ± 0.03 |
 | M10 | 30 | 50 | 97.23 ± 0.41 | 23.12 ± 0.53 | 0.14 ± 0.01 |
 | M11 | 30 | 50 | 99.43 ± 0.73 | 23.74 ± 0.95 | 0.13 ± 0.03 | </md>


[User]
<|image|>Parse the following content of the diagram in markdown code: <md> | Hematological biochemical parameters | Control | CDDP | Calyxin Y | CDDP + Calyxin Y |
 | --- | --- | --- | --- | --- |
 | Aspartate aminotransferase (U/L) | 101.1 ± 2.9 | 158.5 ± 5.1 | 129.3 ± 3.5 |

[Assistant]
160.3 ± 4.7 |
 | Alanine aminotransferase (U/L) | 36.5 ± 3.6 | 40.2 ± 1.2 | 37.5 ± 1.4 | 42.7 ± 1.5 |
 | Alkaline phosphatase (U/L) | 117.2 ± 4.5 | 125.4 ± 0.91 | 115.4 ± 2.7 | 127.6 ± 3.8 | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> |  | Recruitment participants in period | Start SMS weeks in period | Weeks of the year/SMS weeks | Number of invitations |
 | --- | ---

[Assistant]
| --- | --- | --- |
 | Batch 1 | October – December ‘12 | December ‘12 - January ‘13 | 49 to 52 and 01 to 04 | 555 |
 | Batch 2 | November ‘12-January ‘13 | January–February ‘13 | 01 to 09 | 537 |
 | Batch 3 | January – March ‘13 | March–April ‘13 | 10 to 18 | 781 |
 | Batch 4 | March – May ‘13 | May–June ‘13 | 19 to 26 | 795 |
 | Batch 5 | May – July ‘13 | July–August ‘13 | 27 to 35 | 794 |
 | Batch 6 | July – September ‘13 | September–October ‘13 | 36 to 44 | 728 |
 | Batch 7 | September – December ‘13 | November ‘13 - January ‘14 | 45 to 01 | 838 | </md>


[User] <|image|>Convert the image to Markdown syntax.

[Assistant]
<md> | Panel Member | Board Certification | Practice Setting | Practice Location |
 | --- | --- | --- | --- |
 | William Banner, MD, PhD | Pediatrics, pediatric critical care, medical toxicology | Clinical toxicology service, pediatric intensive care unit | Oklahoma City, Oklahoma, USA |
 | Vikhyat Bebarta, MD | Emergency medicine, medical toxicology | Clinical toxicology service, emergency department | San Antonio, Texas, USA |
 | Jeffrey Bernstein, MD | Emergency medicine, medical toxicology, clinical pharmacology | Emergency department, poison center | Miami, Florida, USA |
 | Sean P. Bush, MD | Emergency medicine | Envenomations clinical service, emergency department | Loma Linda, California, USA |
 | Richard C. Dart, MD | Emergency medicine, medical toxicology | Clinical toxicology service, poison center | Denver, Colorado, USA |
 | William P. Kerns, II, MD | Emergency medicine, medical toxicology | Clinical toxicology service, emergency department, poison center | Charlotte, North Carolina, USA |
 | William H. Richardson, MD | Emergency medicine, medical toxicology | Emergency department, poison center | Columbia, South Carolina, USA |
 | Anne-Michelle Ruha, MD | Emergency medicine, medical toxicology | Clinical toxicology service, emergency department, poison center | Phoenix, Arizona, USA |
 | Steven A. Seifert, MD | Emergency medicine, medical toxicology | Clinical toxicology service, emergency department, poison center | Albuquerque, New Mexico, USA |
 | David A. Tanen, MD | Emergency medicine, medical toxicology | Clinical toxicology service, emergency department, poison center | San Diego, California, USA | </md>


[User] <|image|>Convert the photo into Markdown language.

[Assistant]
<md> | Admission to hospital | 29 January 2016 |
 | --- | --- |
 | Operation procedure | 30 January 2016 |
 | Discharge from hospital | 04 February 2016 |
 | Spontaneous vaginal delivery | 04 May 2016 | </md>


[User] <|image|>Render the picture in Markdown format.

[Assistant]
<md> | Study | Filter Type | No. Patients | Duration of Insertion (mean) (days) (range) | Insertion Complication* | Filter Migration | IVC Penetration | Caval Occlusion | Failed Retrieval Rate |
 | --- | --- | --- | --- | --- | --- | --- | --- | --- |
 | Rosenthal et al. 2004[55] | Optease | 94 | 19 (5-25) | 6 (6.4%) | 0 | 1 | 0 | 0/31 |
 | Allen et al. 2005[54] | Gunther Tulip | 51 | NR | 0/51 | 0 | 0 | 0 | 1/25 (4%) |
 | Offner et al. 2003[53] | Gunther Tulip | 44 | 14 (3-30) | 0/44 | 0 | 0 | 0 | 1/40 (2.5%) |
 | Hoff et al. 2004[52] | Gunther Tulip | 35 | 10 (6-14) | 0/35 | 0 | 0 | 0 | 0/18 |
 | TOTAL |  | 224 |  | 6/224 (2.6%) | 0 | 1/224 (0.4%) | 0 | 2/114 (2.8%) | </md>


[User] <|image|>Transcribe the illustration into Markdown format.

[Assistant]
<md> | Groups | Before immunization | After immunization | After injection into the inner ear |
 | --- | --- | --- | --- |
 | Group A | 0.4231 ± 0.0475 | 0.6683 ± 0.0371 | 0.6587 ± 0.0236 |
 | Group B | 0.4345 ± 0.0453 | 0.6506 ± 0.0284 | 0.6468 ± 0.0352 |
 | Group C | 0.4412 ± 0.0435 | 0.6649 ± 0.0403 | 0.6528 ± 0.0416 | </md>


[User] <|image|>Interpret the illustration as Markdown format.

[Assistant]
<md> |  |  | GRNCOP2 | Soinov et al. | Bulashevska and Eils | RANDOM |
 | --- | --- | --- | --- | --- | --- |
 | Yeastnet | precision | 93.33% | 50.00% | 88.89% | 51.58% |
 |  | sensitivity | 14.29% | 3.06% | 8.16% | - |
 |  | specificity | 98.91% | 96.74% | 98.91% | - |
 |  | score | 3.04 | 1.84 | 2.77 | 1.5303384 |
 | Co-citation | Precision | 93.33% | 50.00% | 88.89% | 43.68% |
 |  | sensitivity | 16.87% | 3.61% | 9.64% | - |
 |  | specificity | 99.07% | 97.20% | 99.07% | - |
 |  | score | 3.26 | 1.85 | 2.84 | 1.3487118 |
 | GO | precision | 73.33% | 50.00% | 55.56% | 45.26% |
 |  | sensitivity | 12.79% | 3.49% | 5.81% | - |
 |  | specificity | 96.15% | 97.12% | 96.15% | - |
 | <COLSPAN=2> number of associations | 15.00 | 6.00 | 9.00 | - | </md>


[User] <|image|>Interpret the diagram as Markdown format.

[Assistant]
<md> | Non-Native Species | Site 1 | Site 2 | Site 3 |
 | --- | --- | --- | --- |
 | Fishes |  |  |  |
 | Carassius cuvieri | 0.50 | 0.00 | 0.00 |
 | Channa striata | 0.50 | 0.00 | 0.00 |
 | Oreochromis spp. | 5.00 | 19.50 | 57.00 |
 | Trichogaster trichopterus | 0.00 | 101.00 | 0.00 |
 | Birds |  |  |  |
 | Acridotheres javanicus | 0.00 | 0.33 | 2.00 |
 | Acridotheres tristis | 0.33 | 0.00 | 0.00 |
 | Columba livia | 5.67 | 0.00 | 0.67 |
 | Threskiornis aethiopicus | 2.67 | 0.00 | 0.00 | </md>


[User]
<|image|>Parse the table content behind with markdown code: <md> | <ROWSPAN=2> Measure | <COLSPAN=2> AB | <COLSPAN=2> CD | <COLSPAN=2> P | <ROWSPAN=2> F(2, 148), p |
 | M | SD | M | SD | M | SD |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Unaided baselines |  |  |  |  |  |  |  |
 | HHIE | 27.7 | 13.6 | 29.3 | 17.3 | 29.0 | 16.4 | 0.24, .79 |
 | CST (RAU) | 53.8 | 27.1 | 51.8 | 20.5 | 53.4 | 24.7 | 0.13, .88 |
 | PHAPglobal | 0.36 | 0.12 | 0.38 | 0.13 | 0.40 | 0.13 | 1.53, .22 |
 | PHAPavds | 0.20 | 0.10 | 0.23 | 0.14 | 0.25 | 0.12 | 2.43, .09 |
 | Outcome Measures |  |  |  |  |  |  |  |
 | PHABglobal | 0.17 | 0.12 | 0.12 | 0.12 | 0.04 | 0.10 | 18.56, < .001 |
 | PHABavds | 0.02 | 0.13 | 0.01 | 0.10 | 0.02 | 0.10 | 0.10, .90 |
 | CST benefit (RAU) | 21.3 | 19.4 | 26.6 | 16.1 | 8.7 | 21.2 | 11.78, < .001 |
 | HHIE benefit | 18.2 | 14.2 | 12.3 | 14.1 | 5.5 | 11.6 | 12.09, < .001 |
 | HASShaf | 3.80 | 0.45 |

[Assistant]
3.48 | 0.62 | 3.42 | 0.58 | 6.92, .001 |
 | HASSdisp | 4.56 | 0.28 | 4.23 | 0.40 | 4.52 | 0.43 | 11.40, < .001 |
 | Usage (hours/day) | 7.09 | 3.95 | 6.12 | 3.93 | 5.99 | 3.39 | 1.33, .27 | </md>


[User] <|image|>Transcribe the diagram into Markdown format.

[Assistant]
<md> |  | Cardiac arrest (n = 354) | Hospital non-survivors (n = 204) | Completed questionnaire (n = 81) | GCS score below 6 points (n = 7) |
 | --- | --- | --- | --- | --- |
 | Age in years, mean ± SD | 66 ± 13 | 68 ± 12 | 61 ± 13 | 61 ± 12 |
 | Median (25th/75th percentile) | 68 (60/75) | 70 (62/77) | 61 (53/72) | 64 (50/68) |
 | Gender male/female, number (percentage) | 252/102 (71/29) | 148/56 (73/27) | 57/24 (70/30) | 6/1 (86/14) |
 | ICU stay in days, mean ± SD (minimum-maximum) | 9 ± 16 (1–113) | 8 ± 14 (1–98) | 7 ± 11 (1–78) | 17 ± 23 (2–67) |
 | Median (25th/75th percentile) | 3 (1/9) | 4 (1/9) | 3 (2/7) | 6 (2/18) |
 | Hospital stay in days, mean ± SD (minimum-maximum) | 25 ± 28 (1–176) | 4 ± 18 (1–150)a | 19 ± 18 (1–103) | 35 ± 30 (2–101) |
 | Median (25th/75th percentile) | 15 (5/33) | NA | 14 (10/22) | 26 (15/38) |
 | SAPS II, mean ± SD | 47 ± 23 | 58 ± 19a | 38 ± 20 | 47 ± 21 |
 | Median (25th/75th percentile) | 45 (31/63) | 58 (44/71)a | 33 (23/53) | 53 (24/66) |
 | SAPS II PRM as a percentage, mean ± SD | 42 ± 33 | 58 ± 30a | 42 ± 33 | 45 ± 36 |
 | Median (25th/75th percentile) | 35 (12/74) | 64 (33/85)a | 14 (5/52) | 53 (6/78) |
 | Simplified TISS-28 day 1, mean ± SD | 34 ± 11 | 36 ± 10 | 31 ± 8 | 37 ± 3 |
 | Median (25th/75th percentile) | 34 (28/40) | 36 (28/43) | 32 (26/37) | 37 (34/40) |
 | TMS, mean ± SD | 9.6 ± 5.2 | 11.8 ± 4.5a | 6.3 ± 5.0 | 7.7 ± 5.3 |
 | Median (25th/75th percentile) | 11 (5/13) | 13 (10/15)a | 5 (2/11) | 9 (1/10) | </md>


[User]
<|image|>Parse the photo content behind with markdown code: <md> | Rs10954213 | <COLSPAN=2> Allele | <COLSPAN=3> Genotype |
 | --- | --- | --- | --- | --- | --- |
 | Group | A | G | AA | AG | GG |
 | BPD | 129 | 153 | 33 | 63 | 45 |
 | C | 183 | 197 | 44 | 95 | 51 |
 | MDD | 8 | 6 | 1 | 6 |

[Assistant]
0 |
 | SZ | 100 | 96 | 25 | 50 | 23 | </md>


[User] <|image|>Interpret the figure as Markdown format.

[Assistant]
<md> | Variable | Hypertonic saline (n = 60) | Normal saline (n = 60) | P value |
 | --- | --- | --- | --- |
 | <COLSPAN=4> Demographic and clinical characteristics |
 | Age (years) | 76.6 ± 5.8 | 75.6 ± 5.6 | 0.382 |
 | Sex, female (%) | 31 (52) | 27 (45) | 0.534 |
 | BMI (kg/m2) | 28.7 ± 3.4 | 28.5 ± 3.3 | 0.845 |
 | Education (years) | 9.2 ± 3.3 | 9.6 ± 3.3 | 0.492 |
 | ASA score of 2, n (%) | 38 (63.3) | 35 (58.3) | 0.315 |
 | MMSE (point) | 25.7 ± 1.4 | 25.5 ± 1.3 | 0.343 |
 | Duration of anesthesia (min) | 98.5 ± 12.3 | 102.2 ± 13.3 | 0.113 |
 | <COLSPAN=4> Frequency of comorbidities: |
 | Coronary artery disease, n (%) | 14 (23.3) | 18 (30) | 0.682 |
 | Diabetes, n (%) | 15 (25.0) | 10 (16.7) | 0.261 |
 | Hypertension, n (%) | 47 (78.3) | 50 (83.3) | 0.484 |
 | Cerebral infarction, n (%) | 14 (23.3) | 19 (31.7) | 0.307 |
 | <COLSPAN=4> Cytokines |
 | IL-1β (pg/ml) | 1.33 ± 0.17 | 1.75 ± 0.15 | 0.000 |
 | IL-6 (pg/ml) | 91.03 ± 9.32 | 121.44 ± 9.58 | 0.000 |
 | IL-10 (pg/ml) | 6.89 ± 1.78 | 5.45 ± 1.68 | 0.000 |
 | TNF-α (pg/ml) | 20.64 ± 3.78 | 44.03 ± 3.52 | 0.000 |
 | S100β (ng/mL) | 0.26 ± 0.09 | 0.34 ± 0.11 | 0.000 |
 | CD14 + CD16+ monocytes (%) | 19.70 ± 4.57 | 35.75 ± 4.31 | 0.000 |
 | Prevalence of delirium, n (%) | 7 (11.7) | 23 (38.3) | 0.001 | </md>


[User] <|image|>Translate the illustration into Markdown format.

[Assistant]
<md> | Group | Acupoint | Manipulation |
 | --- | --- | --- |
 | <ROWSPAN=2> Group Atraditional acupuncture | EX-HN 15 (Jingbailao) | <ROWSPAN=2> The needle-punching depth in the each acupoint is 0.5 to 0.8 cun. The sensation (denominated de-qi) is necessary |
 | SI 15 (Jianzhongshu) |
 | <ROWSPAN=2> Group Bacupoints shallow puncture | EX-HN 15 (Jingbailao) | <ROWSPAN=2> The needles are pierced through the skin for 0.2 cun and not enough to produce de-qi |
 | SI 15 (Jianzhongshu) |
 | <ROWSPAN=2> Group Cnon-acupoint acupuncture | Non-acupoint 1 | <ROWSPAN=2> The needle-punching depth in the acupoints is 0.5 to 0.8 cun. The sensation (denominated de-qi) is necessary |
 | Non-acupoint 2 |
 | <ROWSPAN=2> Group Dnon-acupoint shallow puncture | Non-acupoint 1 | <ROWSPAN=2> The needles are pierced through the skin for 0.2 cun and not enough to produce de-qi |
 | Non-acupoint 2 |
 | <ROWSPAN=2> Group Esham puncture | EX-HN 15 (Jingbailao) | <ROWSPAN=2> The placebo needle tip is pressed and fixed on the skin of the acupoint |
 | SI 15 (Jianzhongshu) | </md>


[User] <|image|>Encode the image in Markdown syntax.

[Assistant]
<md> | Tau | Bmax (μM) | Kapp (μM) | R |
 | --- | --- | --- | --- |
 | tau | 2.31 ± 0.05 | 0.03 ± 0.004 | 0.99 |
 | tauPRD | 0.81 ± 0.05 | 0.57 ± 0.09 | 0.99 |
 | tauMTBD | 1.09 ± 0.01 | 0.29 ± 0.01 | 0.99 | </md>


[User] <|image|>Convert the figure into Markdown format.

[Assistant]
<md> | Variable | All HD Patients(N = 33) |
 | --- | --- |
 | Primary renal diagnosis (%) |  |
 | Diabetic nephropathy | 24.2 [8] |
 | Polycystic kidney disease | 15.2 [5] |
 | Renovascular disease | 12.1 [4] |
 | Glomerulonephritis | 24.2 [8] |
 | Unknown cause | 12.1 [4] |
 | Other known | 12.1 [4] |
 | Length of time on HD (mo) | 5.5 ± 2.7 |
 | Mean UF volume (l) | 1.7 ± 1.0 |
 | Dialysis access (%) |  |
 | Fistula | 81.8 [27] |
 | Graft | 3 [1] |
 | Tunneled line | 15.2 [5] |
 | Diabetes [%] | 24.2 [8] |
 | Hypertension [%] | 60.6 [20] |
 | Myocardial infarction [%] | 12.1 [4] |
 | Ischemic heart disease [%] | 18.2 [6] |
 | Stroke [%] | 15.2 [5] |
 | Peripheral vascular disease [%] | 9.1 [3] |
 | Systolic blood pressure (mm Hg) | 138 (131–155) |
 | Diastolic blood pressure (mm Hg) | 78 (67–83) |
 | Hemoglobin (mg/dl) | 111 (103–118) |
 | Urea reduction ratio (%) | 73 (68–78) |
 | Albumin (g/l) | 35 (32–36) |
 | C-reactive protein (mmol/l) | 8 (3–14) |
 | Phosphate (mmol/l) | 1.73 (1.33–2.18) |
 | Corrected calcium (mmol/l) | 2.35 (2.24–2.39) |
 | Parathyroid hormone (mmol/l) | 48.1 (24.5–85.9) |
 | Galectin-3 (ng/ml) | 17.5 (13.4–22.0) |
 | hs-Troponin Ta (pg/ml) | 33.7 (23.5–46.9) |
 | NT-BNPa (pg/ml) | 1934 (1111–5111.5) |
 | ECG QTcb (m/s) | 435 (412.8–453) | </md>


[User]
<|image|>Parse the following content of the figure in markdown code: <md> | Source | d.f. | MS | F | P |
 | --- | --- | --- | --- | --- |
 | Line | 3 | 0.048 | 3.723 | 0.150 |
 | Cactus | 1 | 0.014 | 1.273 | 0.336 |
 | Line × Cactus | 3 | 0.014 | 7.539 | 0.001 |
 | Wing Length | 1 | 0.001 | 0.806

[Assistant]
| 0.372 |
 | Error | 79 | 0.002 |  |  | </md>


[User] <|image|>Render the table in Markdown format.

[Assistant]
<md> | Park use measurement | Sample mean (%) |
 | --- | --- |
 | Loops empty (% of observations) | 35.1 |
 | Average use per hour | 3.8 persons/hr |
 | Average use per week | 291 persons hr/week |
 | Average use by sex |
 | Females | 1.6/hr (43) |
 | Males | 2.1/hr (57) |
 | Average use by age group |
 | Children | 1.0/hr (27) |
 | Teens | 0.4/hr (11) |
 | Adults | 2.0/hr (54) |
 | Seniors | 0.3/hr (8) |
 | Apparent race/ethnicity of users |
 | Latino | 1.1/hr (29) |
 | African American | 0.9/hr (24) |
 | White | 1.5/hr (39) |
 | Asian and other | 0.3/hr (8) |
 | Observed activity levels of users |
 | Sedentary | 0.2/hr (5) |
 | Moderate | 2.9/hr (76) |
 | Vigorous | 0.7/hr (18) | </md>


[User]
<|image|>What are the following photo content in markdown style: <md> | <underline>Category</underline> | <underline>Type</underline> | <underline>Count</underline> | <underline>Percent</underline> |
 | --- | --- | --- | --- |
 | False Positive Calls | Simple False Positives | 8 | 44% |
 | False Positive Calls | Reflected Duplication | 8 | 44% |
 | False Positive Calls | Reflected Overlap | 2 | 11% |
 | False Positive Calls | Total | 18 | 100% |
 | Missed Calls | Too Close | 14 | 58% |
 | Missed Calls | Overlapping Intervals | 3 | 13% |
 | Missed Calls | Ambiguous | 4 | 17% |

[Assistant]
| Missed Calls | Chromosome Ends | 3 | 13% |
 | Missed Calls | Total | 24 | 100% | </md>


[User]
<|image|>What are the following image content in markdown style: <md> | Liking scores | Sex | Mean | SD a | Quartile 1 “Low liking” | Quartile 2 | Quartile 3 | Quartile 4 “High liking” |
 | --- | --- | --- | --- | --- | --- | --- | --- |
 | Fat | Women | 3.75 b | 1.40 | 0.00, 2.76 | 2.76, 3.65 | 3.65, 4.64 | 4.64, 8.80 |
 |  | Men | 3.95 | 1.42 | 0.09, 2.97 | 2.97, 3.86 | 3.86, 4.84 | 4.84, 9.61 |
 | Sweet | Women | 3.64 b | 1.28 | 0.00, 2.72 | 2.72, 3.54 | 3.54, 4.47 | 4.47, 9.35 |
 |  | Men |

[Assistant]
4.03 | 1.35 | 0.12, 3.07 | 3.07, 3.97 | 3.97, 4.94 | 4.94, 9.55 |
 | Salt | Women | 3.76 | 1.52 | 0.00, 2.77 | 2.77, 3.77 | 3.77, 4.72 | 4.72, 10.0 |
 |  | Men | 3.80 | 1.59 | 0.00, 2.76 | 2.77, 3.82 | 3.82, 4.86 | 4.87, 10.0 | </md>